tend season strong anticip gener solid result
earnings-driven biotech innov aliv well among smid cap fair number
event anticip unfortun solid financi perform steadi
pipelin progress may enough improv sentiment toward group long
drug price remain focal point debat
stock lag market generalist continu larg absent
mediocr growth prospect larg cap combin vigor debat drug
price entic contrast specialist engag continu
hunt new idea share sentiment pipelin progress revenu
growth ultim reward focu remain smid cap portion sector
specialist see best prospect meaning catalyst innov product
acceler top line exit expect financi report help support
sector anticip major compani meaning financi post
result least line consensu howev substanti upsid like depend
upon chang sentiment struggl identifi catalyst
expect financi perform fairli idiosyncrat compani howev
macro trend worth consid favor side biotech sale
get boost return price increas lull
mani franchis see full benefit price hike taken tend
exhibit favor season trend thu far biotech compani pre-announce
poor financi howev dollar strengthen versu mani major currenc
creat fx headwind im demand trend remain lacklust sever blockbust
franchis report season investor look evid larg
cap earn healthi host newer product acor inbrija akca tegsedi
nbix ingrezza pbyi nerlynx ptla andexxa rare crysvita rduss tymlo
stml elzonri least meet expect
name best potenti report result excess consensu includ
gwph result
line
expect believ financi perform could disappoint
pleas see page report import disclosur
cowen compani consensu thomson reuter bloomberg compani compil
companytickeranalystreport datepric opinionacadiaacadbaraljuli pima adjunct schizophrenia enhanc trial data expect end narr anticip data includ data expect remain modest akceaakcabarallik august eu condit approv waylivra may expect revenu drive in-lin revenu optimist ultomiri launch drive out-performance alkermesalksshibutanil expect investor need greater visibl growth driver share meaning inflect alnylamalnybarallik august lumasiran inclisiran potenti approv earli amgenamgnwerberjuli anticip upsid consensu estim driven strong top-lin translat higher ep driven neulasta enbrel offset soft aimovig repatha sensipar amicusfoldbarallik august aav gene therapi pipelin add long term valu audent pharmaboldbarallik august believ resolv preclin toxic issu pomp program track file ind given consist clinic result expect clean regulatori path forward xlmtm bold give detail final regulatori path forward program could earli expect gaap ep line street consensu due higher expens celgen product sale china could soft follow strong rebound follow seasonablli weak mix biomarin bmrnnadeauaugust celgenecelgwerberlik juli otezla slightli consensu dynavaxdvaxnadeauearli under-valued heplisav emerg biosolutionsebspeakerl juli earli well driver newli acquir product narcan vaxchora vivotif exelixisexelwerberjuli consensu gilead sciencesgildnadeaujuli overallweexpectasolidquarterfromgild potentialupsidefromthehivandhcvfranchisescouldyieldtotalrevenueandnon-gaapepsaboveourestimateandconsensu thoughtroughearningsareinthepast wesuspectamajorreratingwillrequirebettervisibilityonapipelinecandidatecapableofdrivingareaccelerationinrevenu glycomimeticsglycbarallik late juli need rivipansel potenti peak market opportun gw pharmaceuticalsgwphnadeaulik earli beat estim drug take market share pacira exparel expand extended-releas local anesthet market incyteincyfrahmjuli pipelin cowen
cowen compani consensu thomson reuter bloomberg compani compil
companytickeranalystreport datepric opinioninsmedinsmbarallik late juli launch growth investor focu addit color around launch metric ramp intercepticptbarallik juli guidanc ioni pharmaceuticalsionsbarallik august broaden waylivra fpl trial fxi trial end stage renal diseas ironwoodirwdpeakerl juli earli jolla pharmaceuticalsljpcnadeaulik mid-to-l myokardiamyokbarallik august ph pioneer ole trial key catalyst move forward myovantmyovnadeaulik earli mid report may anticip posit result ph liberti quarter sinc launch orilissa royalti revenu track consensu pacirapcrxpeakerl juli earli quarter well plan recently-acquir iovera estim sale pdl biopharmapdlinadeaulik earli weanticipatefinancialswillbein-linewithourproject withstrengthintekturnabalancingweaknessintheglumetzafranchis pdlseeksspec pharmaproduct withtekturnaandglumetzafacinggenericcompetitionw think good acquisit necessari creat meaning sharehold valu portolaptlanadeauaugust portola hope andexxa ramp drive out-performance ptc therapeuticsptctthome/ baralearli radiusrdusshibutaniearli develop elacestr view underpin potenti posit stock inflect regeneronregnwerberaugust libtayo line praluent continu look sluggish sagesagebaralaugust top-lin data archway studi bipolar depress juli like august therapeuticsstmlpeakerearli avail us sinc end januari eu approv like updat bpdcnpatientpopulationwillbekeyinvestorfocu weareoptimisticontheabilityoflabelexpansionforelzonri cmml/mf ultragenyxrarewerberlik juli over-the-counter would upsid nda file lc-faod expect therapeuticsuthrshibutanil july/earli withsandozfinallylaunchingagenericremodulin welookforcommentaryoncommercialimpact thoughitremainsearli positiveimpactfromfreedom-evcouldrequirealabelchang ralinepagincreasinglyappearstob sole asset could abat forecast multi-year revenu declin though impact would juli earli weanticipatecontinuedsolidperformancefromvertexsmarketedcfproductswithgrowthdrivenbysymdekoseulaunch labelexpansionsandnewterritoryreimburs vrtxremainsatoppickbasedonitsindustry-high revenu growth cowen
broad market support increas optim fed cut
interest rate trade war china europ canada mexico uk
avoid push stock modestli gain preserv
one best stock perform last ten year unfortun
translat stellar biotech fact biotech stock lag meaning
quarter rhetor around drug price health care reform increas
quarter presidenti campaign got underway though polit parti
seem agre littl els democrat republican appear will portray
biopharmaceut industri poor light help biotech stock
perform larg cap-weight nasdaq biotechnolog index nbi fell
smid cap weight amex biotechnolog index btk declin
small cap heavi xbi comparison djia increas
nasdaq composit gain nbi
btk continu healthi gain though lag djia
 perform high
beta xbi somewhat ahead market first half year
hand good pipelin develop coupl high profil acquisit
kept biotech specialist engag continu prospect new idea
hope pipelin progress revenu growth reward specialist also
trade around anticip event clinic trial result notabl earn
report focu remain smid cap portion sector specialist see
best prospect meaning catalyst innov product acceler top-lin
 exit larg cap suffer percept growth-starv
pipelin poor though investor would conced inexpens
cowen compani thomson
contrast specialist investor generalist continu larg absent
biotech late failur biib aducanumab yet anoth remind risk
inher biotech invest even among safer larg cap mediocr growth
prospect suggest suffici return generalist investor assum
risk moreov healthcar drug price major topic
presidenti elect see real prospect generalist return
elect
cowen biotech team increasingli view biotechnolog tale two differ
sector larger matur profit compani begun morph big
pharma smaller innov developmental-stag compani
repres mani tradit thought envis biotech
believ may place larg cap biotech mani investor portfolio
believ compani capabl lead sector rather histori
suggest diseconomi scale drug discoveri poor redeploy capit
limit return segment biotech result expect small- mid-
cap biotech stock outperform time
littl chang impress larg cap biotech face
challeng middl revenu growth poor pipelin product
increasingli difficult payor environ among biotech market cap
excess regeneron worst perform q/q investor
worri eylea futur increasingli cloudi investor fret prospect
cut reimburs intern price index implement
well potenti new competit end averag
biotech enter market cap excess
appreci array sarepta end
market cap former driven acquisit offer
latter increas enthusiasm dmd gene therapi includ array sarepta
analysi larg cap averag q/q specialist recogn
profit larg cap look cheap cant creat roadmap might chang
univers neg percept toward stock even within larg cap group
focu smaller pipelin driven compani
contrast specialist generalist burn repeatedli remind
inher risk aducanumab simpli disinterest
contrast mid cap stock benefit view compani
innov growth-ori larger cap peer riski binari
high beta small cap brethren larg biopharma continu
activ arri hunt next acquisit candid help support
mid cap segment defin market cap averag cowen mid-cap
biotech univers increas best perform mid cap
iovanc present stoke much investor interest tumor
mdco benefit favor
clinic updat laggard
mostli suffer delay disappoint pipelin
stock perform within small cap univers market cap lag two
segment mean perform market unforgiv
commerci pipelin disappoint harshli penal compani balanc
sheet perceiv weak nonetheless number notabl winner
reward market pipelin progress includ
stock perform well
market better understood prospect
laggard featur name financ concern
myov zfgn
one biggest issu larg cap biotech mix financi perform
cours past coupl year earn driven biotech post solid
spectacular result futur financi project adjust
often compani consist beat rais rare combin
percept pipelin lacklust investor grown concern best
day revenu growth earn surpris past investor
look sign larg cap re-establish track record consist
financi perform guidanc increas common cut chart
depict consensu ep expect fluctuat
time includ search sign improv visibl group
competit categori gild hcv biib ms amgn aimovig enbrel g-
csf better read prospect newer drug alxn ultomiri pnh
gild yescarta regn dupix asthma incy/lli olumi nbix/abbv
thomson cowen compani
meanwhil smid cap investor pay close attent plethora new drug
ptla andexxa rare crysvita rduss tymlo stml elzonri
expect financi perform fairli idiosyncrat compani howev
macro trend worth consid favor side biotech sale
get boost return price increas lull
mani franchis see full benefit price hike taken tend
exhibit favor season trend thu far biotech compani
pre-announce poor financi hand dollar strengthen versu
mani major currenc creat fx headwind im demand trend remain
lacklust sever blockbust franchis discuss factor
compani believ like post sale earn excess
consensu includ gwph
compani exhibit sign struggl rel consensu includ
bgne compani anticip report financi less line
demand trend look like mix bag sever blockbust franchis matur
point sale declin although instanc iqvia data may
wholli accur prescrib trend key product includ gild hcv
busi biib ms franchis amgn aimovig g-csf enbrel
lacklust fortun biotech appear midst new product cycl
fda approv nme modern era record follow given
biotech need innov new product financi metric manag
commentari surround new product launch close scrutin mani
new product especi oncolog regn libtayo stml elzonri
orphan categori alni onpattro bmrn palynziq fold galafold gwph
epidiolex insm arikayc alxn ultomiri launch outlook appear favor
chang calendar biotech begun rais price
biotech firm continu practic take substanti price
increas seemingli undet populist critic identifi discret
biotech price increas univers enact januari april
howev dynam seem chang dramat follow
unveil presid trump drug price plan subsequ comment
secretari human servic impli name shame tactic
would employ compani rais price identifi price
increas enact april juli well price increas
identifi lack signific price action
continu price increas well taken
well univers fact
number larger biotech celg pledg rais price
turn calendar self-impos moratorium price increas
laps biotech institut price increas follow bolu
increas fewer though revenu still aid
taken nonetheless level nois attent increas clear
debat drug price stay investor anticip
headlin progress presidenti elect approach
pricerx cowen compani
sale benefit season sale tend season strong
biotech reason explain trend somewhat lack may relat
calendar featur sell day rel vs fewer
vacations/holiday rel rebound demand coupl lower gross
net discount medicar patient exit donut hole favor wholesal
fx headwind compani ex-u exposur valu
dollar strengthen rel rel major foreign currenc q/q basi
dollar strengthen versu brazilian q/q british pound
chines yuan canadian dollar declin modestli versu
mani compani attempt hedg partial hedg exposur expect
strengthen dollar translat somewhat lower ex-u revenu lower ex-
 oper cost compani signific foreign sale
cowen compani compani sec file
last quarter sale deriv
cowen compani
companytickerratinganalystcowen top call earn previewmajor driver drive sept would help stemlin qualit comment manag elzonri cmml/mf agio could engend entic global sale versu consensu acceler due recent approv cowen
guidanc
cowen compani consensu thomson reuter
invest thesi acadia nuplazid pimavanserin approv
treatment parkinson diseas psychosi pdp launch commerci mid-
nuplazid first approv treatment pdp pois fill clear
unmet medic need diseas base annual price per patient us
predict good reimburs see peak us sale peak
ww sale upon eu approv acadia multipl on-going phase trial
pimavanserin follow-on indic includ schizophrenia major depress disord
dementia-rel psychosi drp
nuplazid sale pdp stabil meaning boost dtc campaign
end last quarter think abl meet conserv updat
sale guidanc adjust nuplazid sale estim
base guidanc provid forecast peak sale
long-term care patient penetr retail patient
estim nuplazid sale compar consensu estim
report nuplazid revenu consensu
estim manag note nuplazid
revenu impact usual higher gross-to-net due medicar donut
cowen compani
enhanc trial pimavanserin adjunct treatment schizophrenia enrol
patient inadequ respons current antipsychot treatment
trial start dose mg baselin may titrat mg
mg week treatment depend patient respons background
antipsychot medic allow primari endpoint studi
chang baselin posit neg syndrom scale panss total score
six week treatment top-line data expect
would success outcom look like primari endpoint studi
chang panss score baselin six week believ odd success
somewher given encourag result observ phase studi
non-first episod patient met dsm-iv criteria schizophrenia studi
confirm sub-effect risperidon dose combin pimavanserin provid
faster onset action equal efficaci better safeti compar standard dose
panss baselin placebo group point mean reduct
ri pimavanserin group show improv panss
subscal visit day
bloomberg cowen compani acorda
estim consensu assum rel
modest revenu inbrija launch
feb indic first
major formulari contract sign
june accuraci prescript
unclear find revenu hard predict
though gener erod ampyra
strength ampyra reduc acor
burn project investor seek
assur acor cash suffici fund
compani back profit
report date august confer call et
earn comment anticip call focu almost exclus
inbrija earli trend follow launch februari prescript
grow rapidli q/q accuraci clear moreov first
major formulari contract sign june reimburs access
slower anticip find difficult predict inbrija revenu
accur call expect investor keen better understand
patient demand inbrija acorda progress secur payor access base
physician check continu think inbrija alon support valu
therefor under-valued potenti
fda grant approv inbrija nda decemb inbrija
inhal powder levodopa indic intermitt treatment
episod patient parkinson diseas treat carbidopa/levodopa acorda
launch inbrija februari follow initi market prepar physician
educ field team inbrija price per capsul carton
assum patient fill one scrip per month averag gross-to-net discount
impli annual inbrija revenu per patient
acorda began sampl inbrija april via free starter-pack dose initi
one-month free trial program commerci patient access
sampl first month market inbrija gener
sale acorda indic specialti pharmaci stock inbrija launch
manag believ pharmaci order product satisfi demand
howev acorda know exact proport revenu due channel
earn call may acorda report april receiv
prescript request form inbrija scrip request high-
volum prescrib l-dopa/carbidopa time physician written
prescript inbrija written prescript one patient
impli least scrip total acorda initi market focu movement
disord center treat vast major parkinson patient acorda estim
neurologist account prescript volum make
manag on-going discuss insur secur formulari placement
sever region plan alreadi place inbrija formulari time call
june acorda indic sign first major formulari contract
inbrija distribut network specialti pharmaci manag
uncertain whether publicli avail prescript data accur manag
note iqvia data captur number box written
per prescript current averag prescript includ one box
nonetheless accord iqvia nrx q/q trx
q/q nrx march follow inbrija launch
iqvia cowen compani
inbrija estim consensu find difficult
predict inbrija revenu sinc amount stock unknown
clear prescript trend accur number box per
prescript revenu per prescript avail nonetheless undertook
two analys attempt predict revenu base avail iqvia data
first assum revenu reflect end-us demand iqvia prescript
captur rate chang q/q number box per prescript
remain constant assumpt suggest inbrija q/q revenu growth would
track growth prescript base analysi inbrija revenu would
track toward q/q suspect analysi provid
revenu estim like report revenu probabl channel
inventori stock nonetheless provid one bookend possibl
second assum iqvia captur prescript averag
box inbrija per prescript net revenu per box less
gross net assumpt inbrija would track toward
revenu somewhat short estim consensu
visibl inbrija revenu limit expect trajectori becom
clearer
acorda file march acorda submit respons day list
question ema decis expect
model assum patient use one carton per month gross-to-
net wac per carton assumpt impli cost
per dose per patient per year estim parkinson
patient eu experi episod
project inbrija therapi world-wide
inbrija estim
physician optimist inbrija treatment consult
continu think inbrija address unmet need physician survey prior
confer estim parkinson patient
experi episod could benefit adjunct rescu therapi panelist
think underestim within year two patient begin develop
period four five year number patient suffer closer
parkinson diseas caus problem gut motil lead
unpredict absorpt oral administ l-dopa make oral l-dopa
unattract therapi on-demand manag episod panelist
think avail well-toler on-demand therapi help patient
manag episod bridg regular oral dose levodopa
physician think pd patient could benefit rescu therapi period
cowen compani confer
major survey physician expect inbrija captur least pd
patient episod first year launch strang ask mani
patient use inbrija three year physician give virtual ident
answer panelist optimist expect given avail free sampl
inbrija neurolog offic mani patient go least tri inbrija think
somewher patient period tri inbrija mani
like continu therapi harder predict wide tri
cowen compani confer
cowen compani confer
panelist note efficaci shown inbrija clinic trialsspecif
separ placebo soon minut inhal mainten
effect minutesi import patient experi somewher
minut period almost everi dose l-dopa inbrija
potenti amelior bothersom episod
given inbrija on-demand therapi key investor question frequent
parkinson patient use inbrija treatment episod survey
physician think patient use inbrija somewher four seven time
per week panelist think two group patient term frequenc
use half use inbrija approxim twice per day studi
conduct acorda patient permit use inbrija five time
per day half keep inbrija hand use sparingli use might
restrict special situat patient eaten high protein meal
instanc need sure optim mobil estim patient
might use inbrija time per week
cowen compani confer
sunovion delay time refil unclear
develop sublingu formul apomorphin treatment
episod patient parkinson diseas phase studi led
signific placebo-adjust reduct updr score seem
somewhat potent inbrija howev sublingu apomorphin side
effect inbrija includ nausea somnol dizzi
typic requir co-administr antiemet januari sunovion receiv
complet respons letter fda respons nda submiss apl-
sunovion commun fda request addit inform
analys addit clinic studi would requir resubmiss
sunovion provid estim resubmiss might take place
much delay repres develop say
would work fda address request bring market
expediti possibl therefor amount time take
sunovion answer fda concern refil unclear delay
approv posit acorda increas inbrija lead time market
allow inbrija capit first mover advantag captur patient
maintain share market sublingu apomorphin launch
physician survey prior confer expect littl uptak
sublingu apomorphin parkinson market three year plural
survey physician estim less use drug
panelist disappoint think apomorphin
robust molecul rapidli control motor symptom parkinson suspect
eventu win approv captur patient current
apokyn small number patient tri inbrija experienc
undesir side effect like cough patient would otherwis use inbrija
unabl due pulmonari disord patient take inbrija curiou
tri anoth agent think biggest opportun howev
come patient need potent regimen order go full
state full
cowen compani confer
ampyra sale acorda report ampyra sale q/q
y/i sale estim q/q y/i street
consensu q/q y/i given launch dalfampridin
gener begin septemb ampyra sale expect continu
declin
iqvia report prescript q/q suggest moder
rate declin versu scrip declin q/q march price
gener dalfampridin cut per packag
ampyra togeth prescript trend price decreas would impli ampyra
revenu would q/q gener continu erod
ampyra revenu would appear track well ahead estim
iqvia cowen compani
ep balanc investor close monitor acor cash burn
debat whether acor current cash suffici fund acor oper back
profit end cash convert debt
project non-gaap ep consensu model
project burn approxim cash ampyra
record revenu analysi suggest would burn
non-gaap ep would model project acor cash balanc
abl fund oper back profit though cash would quit low
model assum rais
thesi sever dalfampridin gener launch expect ampyra
revenu continu declin howev continu think acorda
under-valued inbrija inhal l-dopa inbrija approv fda
decemb review ema decis expect
acorda launch inbrija februari follow initi market
prepar physician educ field team consult impress
inbrija profil anticip wide use
parkinson diseas patient experi episod project inbrija
achiev revenu grow
look potenti ema approv inbrija potenti ex-u
commerci partnership inbrija possibl partnership purchas
acorda non-cor pipelin candid possibl updat develop
arucs-bas treatment migrain
idhifa royalti estim slightli
consensu consensu estim set celg
tibsovo sale estim
consensu estim
total revenu estim slightli
consensu estim
ep primari near-term focu investor
agio cowen compani consensu thomson idhifa use celg analyst consensu agio pharmaceut tibsovo
earn summari look earn updat focu whether
deliv commerci sale expect tibsovo wholli own
aml follow disappoint result round toward first full year sale
sinc juli approv base manag commentari tone regard
appar strengthen volum trend resum start quarter
coupl earlier anticip fda label expans decis enabl use
first-lin treatment set believ estim
slightli consensu achiev look idhifa sale result
typic report partner celgen advanc agio result provid
indic franchis perform consensu project idhifa
correl royalti estim beyond commerci
result look updat includ statu on-going dose-
escal studi disclosur initi clinic data
present continu label expans effort tibsovo includ enrol statu
agil trial tibsovo azacitidin newli diagnos aml patient
inelig soc plan cholangiocarcinoma full data present
expect esmo snda file expect mitapivat
pyruv kinas defici enrol two pivot trial activ
activate-t expect complet
tibsovo tibsovo ivosidenib wholli own inhibitor approv fda
juli treatment adult relapsed/refractori acut
myeloid leukemia recal report disappoint result
revenu repres q/q sequenti declin
report come intern street expect manag
attribut slower expect growth primarili season factor includ
greater expect increas portion patient receiv free drug part
compani patient assist program manag also note appar
strengthen volum exit first quarter appar continu april
importantli see earlier anticip success label expans earli
may driver underli expect tibsovo sale resum
solid trajectori recal label enabl treatment newli diagnos patient
aml least year age comorbid preclud use
intens induct chemotherapi estim q/q
slightli ahead consensu q/q tibsovo launch
 price note price increas taken juli
beyond initi commerci launch execut look tibsovo long-term
growth outlook shape approv launch eu
submit ema back decemb peg potenti approv
commit launch product expans within
aml agio studi aim first-lin aml set includ
phase agil trial tibsovo azacitidin patient newli diagnos
mutant aml elig standard induct consolid therapi
expect complet enrol phase trial tibsovo
idhifa combin standard induct consolid therapi fit patient
newli diagnos idh-mut aml use tibsovo compon
combin explor investigator-sponsor trial triplet
combin tibsovo venclexta azacitidin beyond aml see potenti
heighten appreci tibsovo opportun solid tumor set full
result posit phase claridhi trial tibsovo cholangiocarcinoma
present upcom esmo meet sept oct snda
submiss indic expect year-end
idhifa idhifa enasidenib inhibitor partner celgen gain full fda
approv treatment adult relapsed/refractori aml
august idhifa launch price price
increas januari follow januari
announc bristol-my squibb acquisit celgen agio
manag note anticip commerci structur
implic exist partnership celgen
consensu idhifa sale estim among celgen analyst
impli would garner royalti line
estim recal four previou quarter
celgen report quarterli idhifa sale
respect agio book royalti
model idhifa royalti climb unadjust note
tier royalti ramp base idhifa sale
select potent oral avail inhibitor expect
activ cancer mtap delet cancer mainli solid
tumor lymphoma agio current evalu phase dose-
escal trial multipl type mtap-delet tumor agio expect complet
dose escal initi dose expans plan dose-expans cohort
includ two combin cohort one docetaxel mtap-delet non-
small cell lung cancer one nab-paclitaxel gemcitabin mtap-
delet pancreat ductal adenocarcinoma monotherapi basket cohort
enrol patient varieti mtap-delet cancer look manag
disclos initi clinic result dose-escal portion
on-going phase studi present
mitapivat agioss lead candid area inborn error metabol
asset current pivot trial pyruv kinas pk defici rare diseas
caus mutat pkr gene character potenti sever hemolyt
anemia mitapivat alloster activ variou form mutant pkr enzym
shown increas hemoglobin phase proof-of-concept studi
drivepk agio initi two phase studi mitapivat pk defici one
transfusion-depend patient activate-t initi april anoth
non-transfusion-depend patient activ initi june full enrol
pivot trial expect believ mitapivat clinic
commerci potenti pk defici remain rel underappreci
success develop could lead market opportun moreov agio
expect achiev phase proof concept mitapivat thalassemia
vorasidenib pan-idh inhibitor develop low-grad glioma
phase trial vorasidenib achiev stabl diseas rate partial respons rate
minor respons rate non-enhanc glioma
challeng diseas separ phase periop trial level reduc
ci ci patient
treat tibsovo vorasidenib respect compar control
agio decid take vorasidenib rather tibsovo forward glioma base
part lower variabl result agio expect initi pivot trial
dhodh inhibitor enter phase trial lymphoma agio
yet provid guidanc expect data clinicaltri gov state
trial expect achiev primari complet juli
thesi share trade bottom end rang
see opportun share driven potenti sentiment improv across
three key domain name growth outlook commerci idh franchis
success advanc addit pipelin asset confid compani
strateg outlook amidst manag transit compani continu evolv
grow capabl fulli integr biopharma believ deliveri
consist commerci result meet expect start address
current competit concern amidst rapidli evolv aml treatment landscap
suffici help strengthen share compani track record term
deliv regulatori achiev impress look attain
time approv cholangiocarcinoma bolster confid tibsovo
opportun set solid tumor current level believ temper
expect potenti transform asset potenti relev use
cancer provid attract setup initi clinic data help
drive rebound share well head look avail data
mitapivat program broaden appreci compani
look earn report look result provid
reassur regard agio commerci execut capabl help build
confid long-term growth opportun tibsovo regard
sens becom temper investor expect look tone
updat dose-escal dose-expans studi progress well specif
disclosur time format initi clinic data enabl novel
pipelin asset re-insert potenti catalyst year-end mitapivat pkr
inhibitor dont expect materi chang pivot trial statu timelin pk
defici look color regard phase proof concept
thalassemia expect dhodh inhibitor see
potenti increment updat phase trial patient lymphoma
includ timelin initi data disclosur
cowen compani consensu thomson reuter
invest thesi akcea late-stag biopharmaceut compani focus
develop commerci novel therapi patient rare
diseas akcea develop waylivra triglyceride-low drug two rare
sever genet disord fc fpl ema chmp recommend condit approv
waylivra treatment famili fc may receiv
fda waylivra last year tegsedi develop treatment
polyneuropathi associ httr approv octob us
canada base annual price per patient us project peak us sale
mm peak ww sale bn akcea also develop three
earlier stage candid akcea-apo -lrx akcea-apociii-lrx
develop collabor novarti use potenti larg popul
elev cv risk due hypertriglyceridemia akcea develop
independ narrow hyperlipidemia patient popul
akca/ion tegsedi receiv fda approv polyneuropathi hattr black
box warn increas risk thrombocytopenia glomerulonephr octob
therapi strict rem requir least weekli platelet monitor
model tegsedi revenu vs consensu
vs consensu estim tegsedi captur
minor share ttr market europ total revenu
earn call report first quarter post-launch tegsedi
revenu revenu tegsedi recogn sell-in method
distributor take titl assum risk ownership note tegsedi sold
four-dos pack pack serv one unit indic us coverag
discuss encourag continu progress current prescrib
physician includ neurologist cardiologist hematologist patient
cover public privat plan note rem certif
process complianc weekli platelet monitor impact tegsedi
adopt indic complianc monitor excel
anticip tegsedi beat street estim due rollov patient
expand access program adopt rate next quarter
recal licens tegsedi commerci right latam caribbean
compani estim around hattr patient south
america larg number driven portugues founder effect brazilian
popul although note appear patient argentina
origin expect regulatori author brazil anvisa grant prioriti review
tegsedi potenti approv expect
may receiv formal condit approv waylivra
ec adjunct diet genet confirm adult fc patient risk
pancreat respond avail therapi think label best-cas
scenario waylivra europ patient popul recommend
waylivra reason broad ions/akca believ least current
diagnos fc patient identifi mutat part condit
market author ions/akca conduct post author safeti
studi ions/akca leverag infrastructur alreadi place tegsedi
monitor patient safeti ions/akca intend launch waylivra standard
stagger fashion across eu given country-by-countri reimburs process
begin launch germani expect eu contribut
waylivra also develop fpl patient sinc fpl patient function
lpl disinhibit lpl enzym potenti decreas triglycerid even
significantli fc phase broaden studi initi novemb
trial expect enrol approxim patient studi
durat follow option open-label extens enrol patient
undergo diet stabil period random receiv weekli
subq inject placebo waylivra week primari efficaci
endpoint percent chang fast triglycerid baselin three month
dose data broaden expect
conduct phase clinic studi akcea-ttr-lrx lica platform
successor tegsedi compani plan develop therapi hattr well
wtattr data expect pivot develop fap wt/fac
plan trial detail releas closer pivot trial start
overal expect continu growth gmg off-set patient
transfer ultomiri lead revenu least line
ultomiri launch continu convert soliri patient
per month may june approx would
convert end gener revenu
estim consensu
alexion call metabol sale begin
earli alexion proactiv offer rebat
largest vial strensiq
littl visibl if/when sale might becom meaning
ep excl stock option expens non-cash tax cowen compani consensu alexion
report date wednesday juli open cc dial us
confer id
earn summari investor focu alexion abil transfer soliri pnh patient
ultomiri soliri growth new indic prospect competit
alexion franchis earli datapoint suggest ultomiri launch
go well ultomiri approv late decemb april soliri
pnh patient enrol onesourc alexion patient access program
initi treatment ultomiri analysi suggest revenu least
ahead consensu alexion manag state goal
convert least pnh patient soliri ultomiri earli
trend suggest goal exceed meanwhil soliri continu perform
well estim project modest q/q contract reflect impact ultomiri
 well ex-u tender order receiv howev analysi
suggest growth gmg off-set loss patient ultomiri result
less flat q/q revenu in-lin consensu competit front
notabl develop oral proceed held european
patent offic septemb discuss new composit matter method
use patent soliri previous reject epo think alexion
face uphil battl get patent issu howev amgn biosimilar
advanc yet year market think suffici time
transfer much eu market ultomiri prior biosimilar launch remain
hope continu execut launch ultomiri soliri new
indic reinvigor investor interest
call discuss topic expect alexion confer call focu
updat datapoint ultomiri launch includ germani expect
european patent offic oral proceed sept potenti eu biosimilar
entri base busi soliri gmg pnh ahu soliri launch nmosd
expect readi use phase ii/iii program year end
upsid estim consensu ultomiri estim
q/q consensu q/q alexion disclos
 pnh patient begun therapi ultomiri januari
februari march april respect importantli manag expect
convers continu linear rate due segment market typic
rare diseas need physician educ benefit ultomiri
sticki soliri among patient approxim pnh patient
transit ultomiri everi month sinc januari commentari suggest
soliri pnh patient might initi treatment end may
end june
estim pnh patient treat soliri
ultomiri requir load dose follow mainten dose week later
everi week thereaft assum may june soliri patient
transfer ultomiri would impli approxim patient receiv
load dose first mainten dose month patient initi
ultomiri soon drug launch earli januari receiv third mainten
dose may initi treatment februari receiv second
mainten dose april third june initi treatment march
receiv second mainten dose may start april receiv
second mainten dose june altogeth suggest
approxim patient receiv load dose mainten dose
administ ultomiri price per vial dose
depend patient weight adult averag weight load dose
ultomiri cost mainten infus cost thu
analysi would suggest ultomiri sale due load dose
due mainten dose total revenu ahead
estim consensu addit upsid possibl treatment-nav pnh
patient initi ultomiri model growth alexion penetr
pnh market translat approxim treatment-nav patient
initi ultomiri cours year therefor would appear even
ultomiri launch deceler estim consensu appear achiev
ultomiri approv eu juli launch germani follow juli
licensur ema ultomiri earli day launch germani launch
addit european countri pend local fund agreement germani first
year launch involv open price set alexion alexion work
feder joint committe g-ba come agre upon price subsequ year
alexion expect achiev price pariti world-wide alexion expect
fact ultomiri price discount soliri
mainten view favor g-ba given ultomiri initi cost-
neutral patient switch eventu cost save mainten
ultomiri also approv pnh japan market author issu
june launch anticip regulatori file submit
switzerland australia korea columbia israel though cadenc pnh patient
visit physician vari countri month yearli alexion believ
achiev rate convers ex-u achiev least convers
within two year commerci launch
soliri sale soliri estim q/q y/i consensu
q/q y/i overal expect continu growth gmg off-set
patient transfer ultomiri lead revenu least line
underli trend soliri appear solid alexion report patient
demand soliri grew y/i though sale also favor impact
approxim addit tender order ex-u rel revenu
growth driven primarili strength y/i net product sale
partial impact convers pnh patient ultomiri japan
y/i net product sale grow contribut gmg expect
largest indic patient volum soliri alexion manag
indic expect soliri volum growth high singl digit
soliri revenu impact ultomiri convers note
estim approxim pnh patient transit soliri
ultomiri assum discontinu soliri rel
constant pace quarter given patient must stop take soliri two
week initi ultomiri impli soliri would lost approxim
patient-month pnh revenu ultomiri soliri mainten dose
everi week per month impli therefor
estim pnh patient convert soliri would pose
approxim headwind soliri report revenu
gmg expect largest indic soliri soliri uptak gmg
impress steadi sinc soliri launch indic decemb
patient start treatment week compani
earn alexion report gmg initi soliri treatment mid-
april march manag expect gmg
largest patient volum indic soliri year-end
gmg soliri dose weekli first week follow
week everi two week soliri price per
therefor first month gmg patient gener revenu
mainten phase gmg patient gener revenu
estim patient mainten soliri april
patients/month initi therapi would impli sale soliri gmg
ahead estim
therefor growth gmg would off-set revenu lost ultomiri drive
soliri sale least line consensu
given market size broad prescrib base prescrib depth
prescript trend approxim prescrib soliri one gmg patient
expect continu growth gmg sale addit though
discontinu rate seen pivot trial due non-respond
manag state real-world discontinu rate like fall
somewher seen pnh ahu assum annual
discontinu rate pnh discontinu rate ahu challeng
estim given subset patient treat acut think gmg
discontinu rate could fall
soliri also approv gmg europ august japan decemb
though european launch mainli germani slow alexion manag
indic near-term commerci opportun japan promis
could add drug earli sale trajectori
protect soliri extend japan composition/ formul patent
issu novemb three patent issu august
extend howev european patent offic reject new composit
matter method use patent soliri alexion request oral proceed
discuss patent set occur septemb manag
hope three-person panel instead review patent
issu soliri lack patent protect begin eu
soliri sale howev amgen phase trial get underway impli
launch would like year suffici time
transfer soliri patient onto ultomiri
nmosd becam soliri fourth fda-approv indic june alexion
recent neurolog indic soliri nmosd patient
estim diagnos nmo popul june soliri becam first
fda-approv treatment nmosd typic treat
immunosuppress therapi prescrib label soliri approv nmosd
base compel efficaci result reduct relaps risk phase
maintain three year extens trial patient
soliri expect use fail safe treatment relaps patient
sever symptom major impedi adopt among nmosd patient earlier
diseas cours soliri infus regimen given diseas
silent month attack patient may believ long-term benefit
treatment outweigh inconveni regular infus addit standard
care immunosuppress therapi rituxan reduc relaps risk patient
treat medic thought gener content alexion
anticip soliri uptak nmosd progress rel slowli initi adopt
believ soliri use primarili treatment relaps patient
sever symptom prior check consult recogn acut need novel drug
treat patient refractori nmosd patient
major risk blind morbid mortal estim
approxim refractori nmosd patient
develop geographi model ww sale ramp
primarili among refractori patient minor sale
come nmosd patient mostli complet
control exist therapi might difficulti side effect
toler current medic consist estim
half patient would qualifi prevent trial
soliri face addit competit space notabl roch
satralizumab human recycl receptor mab phase soliri
favor risk reduct rel satralizumab vs thu expect
satralizumab use mostli nmosd patient seroneg
approxim soliri captur relapsed/refractori nmosd patient
took differ tack pivot trial inebilizumab nmosd enrol
seroneg patient random double-blind trial inebilizumab
monoclon antibodi target produc reduct risk rel
placebo total inebilizumab-tr patient popul week
reduct risk attack among nmosd patient
though risk reduct less potent soliri satralizumab inebilizumab
may optim posit treatment patient mostli
complet control exist therapi patient difficulti
side effect toler current medic compani plan file
bla fda
announc fda accept prioriti review compani sbla
ultomiri atyp hemolyt urem syndrom ahu set pdufa date
octob sbla base result ultomiri singl arm phase trial
treatment naiv adult ahu week patient ci
demonstr complet tma respons primari endpoint trial tma
respons defin coincid lactat dehydrogenas ldh platelet count
normal alongsid improv serum creatinin least
alexion aim convert ahu patient soliri ultomiri within two
year launchth ambit set pnh steeper price
discount ultomiri ahu year mainten like
increas rate convers
ultomiri conveni benefit vs soliri also particularli
meaning ahu given silent diseas alexion conduct genotyp
phenotyp studi determin percentag ahu patient need chronic
therapi manag estim patient polymorph
complement cascad lead subclin symptom gradual develop
renal diseas patient tma event tend occur associ
infect precipit factor though patient may opt
chronic therapi ultomiri conveni benefit may provid compel rational
initi treatment allow expans ahu market conveni
benefit heighten introduct higher concentr
ultomiri infus minut vs hour current
meanwhil weekli subq formul ultomiri progress develop
on-going phase trial pnh would allow file potenti approv
pnh ahu alexion also develop subq
version ultomiri potenti file launch indic yet
epitop bind soliri strong valu proposit price
discount soliri along fewer infus contribut rapid facilit
convers ultomiri success lessen risk franchis soliri
biosimilar well rais bar futur brand competitor
nonetheless competit continu larg overhang alexion stock brand
competitor includ compani target pnh complement inhibit earlier
cascad apelliss sub phase develop pnh data
anticip late aim differenti mode administr
regeneron subq move phase ii pnh durat action
biosimilar front known compani pivot trial
phase initi april estim complet date februari
program succeed phase launch would follow ultomiri
yearsat point expect major patient convert soliri
ultomiri
asfotas alfa enzym replac therapi treatment hypophosphatasia
approv japan europ strensiq experienc
one best ever orphan drug launch first full year
 market drug launch reimburs countri compani
continu work secur addit ex-u agreement diagnosi
typic made use alkalin phosphatas alp level patient age older
howev pediatr case undiagnos use method due incorrect
refer rang thu alexion begun calip initi educ lab
alexion report strensiq sale y/i stresiq solid
underli volum growth y/i revenu reflect impact
strateg price decis support sustain given weight-bas dose
estim q/q y/i consensu q/q
y/i expect continu penetr newli reimburs territori drive
revenu least line estim consensu
kanuma modest contributor alexion acquisit synageva primarili
base potenti kanuma enzym replac therapi ert
lysosom acid lipas defici lal-d drug launch germani octob
 januari sale fallen well short
expect synageva acquisit ill-conceiv
alexion continu identifi new lal-d patient aim improv ex-u fund
agreement howev sale kanuma modest show littl sign
inflect report revenu y/i kanuma sale estim
y/i consensu project q/q y/i
invest thesi new manag done admir job stabil
compani grow soliri sale pnh ahu launch drug gmg
indic think favor financi outlook increas confid
compani abil convert patient ultomiri could posit share re-
rate investor gain confid growth durabl complement
franchis alexion one larg cap biotech solid growth
prospect reason likelihood continu execut improv investor
sentiment consid top larg cap pick maintain price
look ultomiri launch addit ex-u countri epo oral
hear soliri new patent septemb possibl file high concentr
ultomiri reduc min infus time possibl initi first-in-human
studi bi-specif possibl fda approv ultomiri ahu
cowen compani consensu thomson
vivitrol sale estim
consensu guidanc
aristada sale estim
line consensu
within guidanc rang
total revenu estim
line consensu
within guidanc rang
ep estim
consensu within guidanc rang
earn summari expect earn report focu vivitrol
aristada sale trend well upcom pipeline-rel event vivitrol
debat center whether growth continu deceler regain stabil
base analysi prescript trend project revenu
y/i would repres stabil slight improv
y/i pace report aristada exit strong
unexpectedli miss inventori drawdown look post
result better reflect underli unit growth/demand trend term
pipelin look manag discuss implic
recent announc file nda aim broader label includ bipolar
disord well schizophrenia consequ push file timelin
monotherapi combin studi
iv subq formul continu look updat time data
present program updat partner top-lin
result head-to-head studi versu tecfidera could come
time preced anticip approv
vivitrol project vivitrol sale q/q y/i
slightli consensu base prescript data expect
gross-to-net remain rel stabl rang chang
forecast price forecast midpoint vivitrol full year
guidanc rang impli y/i growth rang
term underli metric expect updat number vivitrol treatment
program us grown start
start start start help yet
qualit refer point legisl updat continu direct increment
financi resourc toward treatment program though pace fund
avail appli level state program move deliber still
difficult predict pace longer term continu believ vivitrol franchis
posit underli fundament support growth low double-digit
aristada estim sale q/q y/i
slightli consensu base histor correl
prescript data trend recal result unexpectedli fell short
expect manag cite inventori drawdown channel
manag lack visibl view result rebound base
primarili strength underli demand trend indic prescript data
aristada navig way past year within market exist
competitor among arguabl lot differenti
approv aristada initio formul help gain share inject
longer-act agent categori initio profil facilit initi therapi faster-
dissolv initio formul enabl therapeut drug level achiev
rapidli reduc need pre-inject oral supplement
announc posit top-lin result phase alpin studi aristada
initio invega sustenna highlight contrast mainstream clinician
percept aristada efficaci par invega slightli prefer
toler profil studi outpati mainten treatment consist aristada
mg administ everi two month invega sustenna mg administ
everi month invega sustenna initi two load dose administ one
week apart alpin studi met primari endpoint reduct panss score
baselin week point aristada point
invega sustenna efficaci similar statist differ
arm addit patient receiv aristada patient
receiv invega sustenna complet six-month studi could indic
improv toler aristada aristada sale estim
line consensu estim lower end compani
guidanc aristada wac increas januari
juli februari
lead late-stag pipelin asset novel broad-spectrum
antipsychot compris olanzapin ingredi commerci success
side-effect-laden zyprexa co-formul alkss proprietari
samidorphan four-week efficaci studi compar
versu placebo acut schizophrenia patient compar arm olanzapin
includ studi enrol patient announc posit top-lin
data june arm show superior efficaci compar
placebo similar efficaci compar olanzapin panss score endpoint
second pivot trial six-month head-to-head studi focus
compar key advers effect weight gain versu olanzapin
adult schizophrenia top-lin result announc novemb
posit mean weight gain reduc patient
treat olanzapin gain baselin bodi weight
compar patient treat co-
primari endpoint third phase studi enlighten-earli examin
extent weight gain young adult began june continu enrol top-
line result expect
juli announc revis plan nda follow
discuss fda rather submit nda schizophrenia
compani plan submit nda schizophrenia bipolar disord
note financi guidanc regard oper expens
point includ assumpt increment cost specif associ
launch manag mention
contempl potenti provid basi
compani establish commerci presenc eu
conduct phase trial solid tumor patient assess
safeti efficaci novel select effector cell activ seca
design activ immunostimulatori receptor believ
overcom limit exist therapi activ
immunostimulatori immunosuppress receptor dose-escal stage
phase trial intraven iv formul on-going maximum
toler dose reach announc june dose-
expans stage begun plan enrol patient renal cell
carcinoma melanoma already-approv indic receiv iv
formul posit pharmacodynam result initi present
novemb aim show monotherapi efficaci data
suspect trial also began evalu
combin keytruda septemb start second phase
trial februari evalu subcutan formul
first monotherapi combin keytruda subcutan
formul dose everi week everi three week expect go-
forward formul assum efficaci profil suffici
compar iv formul
vumer novel oral fumar diroximel fumar develop
multipl sclerosi novemb announc global licens
collabor agreement develop commerci
exclus world-wide licens commerci drug entitl
receiv mid-teen percentag royalti world-wide net sale alkerm maintain
respons regulatori interact approv elig receiv
point receiv june review
gi toler data addit pay high single-digit low
double-digit tier royalti net sale product initi result
phase safeti studi patient present
ectrim confer octob continu show good gi
toler low rate discontinu due gi advers event top-lin result
head-to-head phase studi gi toler
versu tecfidera patient expect pk
bridg studi show bioequival tecfidera requir studi evolve-
elect studi nda referenc tecfidera
regulatori pathway file decemb pdufa date
invest thesi invest thesi share base compani
abil drive commerci success wholli own product portfolio vivitrol
aristada well success develop late-stag pipelin asset aim
neurolog psychiatr diseas believ current level reflect investor
skeptic regard commerci prospect prospect vivitrol
growth meaning re-acceler see potenti vivitrol growth stabil
given unrel demand addict treatment aristada resum
perform rang expect timelin progress
regulatori process coupl potenti aggress stanc busi
develop front reinvigor pipelin could provid catalyst drive
posit inflect share
look earn report vivitrol aristada sale
driver metric look commentari full-year guidanc
rational ad bipolar disord nda schizophrenia expect
updat strategi oncolog tradit
therapeut area time data expect partner
expect top-lin result regulatori
process approv expect
cowen compani consensu thomson reuter
invest thesi think alnylam leader field rnai therapeut
compani built strong ip posit around construct deliveri
technolog taken modular approach drug develop alnylam lead
candid onpattro fka patisiran report posit diseas revers phase
result treatment fap ttr amyloidosi receiv fda ema approv
fap august advanc pipelin program solid driver long-term
valu provid steadi catalyst flow two potenti launch
next month full top-lin analysi pivot phase trial givosiran
acut intermitt porphyria aip present easl report strong result
outlin accept risk/benefit profil alnylam alreadi initi roll nda
pursu full regulatori approv givosiran complet fill approv
eu see strong chanc approv commerci success follow potenti
earli approv think inclisiran hypercholesterolemia
lumasiran primari hyperoxaluria type next catalyst readout late
potenti approv earli top-lin data phase atla
program sny-partn fitusiran hemophilia also expect mid-to-
look onpattro sale inclisiran full phase data
onpattro patisiran us eu fap launch continu
project onpattro sale line consensu forecast
onpattro sale exceed model estim
consensu report revenu reflect patient
commerci onpattro us/eu doubl patient
end major sale came us though expect eu sale
increas end onpattro alreadi avail countri
payor feedback encourag addit launch also pend canada
japan manag encourag earli momentum particularli
given on-going tafamidi eap program tegsedi avail
patient referr form prf count patient also suggest strong
prescript rate number lower report last quarter
previou prf bolu patient eap program other
exist patient apollo investig vs eap patient
believ fair comparison vs think updat
metric point increas real world uptak suggest onpattro continu
commerci reach furthermor indic alnylam manag prf
captur prescript process alnylam hub current
constitut total form estim us suggest limit
reimburs hurdl patient doctor navig insur help
revenu estim impli reason q/q growth model
project onpattro revenu us europ
may receiv earli fda approv tafamidi treatment
wt/hereditari cardiomyopathi ttr attr-cm adult given result
mortal reduct highlight label tafamidi may like becom soc attr-
cm think price sever limit use think partial
mitig tafamidiss potenti commerci threat onpattro alni ttr franchis
although final impact remain seen
inclisiran hypercholesterolemia mdco-partn inclisiran aln-pcssc
program target hypercholesterolemia inhibit inclisiran work
degrad mrna insid cell therebi prevent product
protein lower receptor intern lower level -c think
inclisiran uniqu offer possibl everi month dose
minim although earli data suggest efficaci low end competit
spectrum partner mdco initi phase trial inclisiran
heterozyg famili hypercholesterolemia hefh atherosclerot
cardiovascular diseas ascvd ascvd-risk equival top-line readout
remain track like follow nda file pend
expect singl digit y/i price declin volum
hold steadi sale like beat season
upsid possibl neulasta inline/bett
track consensu
sale trajectori remain neg
product track consensu us
ww sale
track consensu
parsabiv track consensu sensipar
like consensu depend gener entri
track consensu
track slightli consensu
trackng line consensu
track consensu
aimovig scrip trend suggest revenu
includ blincyto corlanor imlyg biosimilar
expect upsid consensu estim
expect upsid consensu estim
cowen compani consensu
expect cost save share repurchas
bring ep consensu
report date tuesday juli confer call et
call number
model updat trim total revenu estim
mm new ep estim
earn summari prescript trend sever franchis neulasta
parsabiv epogen prolia enbrel expect come somewhat consensu
xgeva aranesp sensipar aimovig kyproli repatha track behind
balanc think consensu total revenu estim beatabl think
financi flexibl abil control cost repurchas share
also result non-gaap ep consensu
 product sale appear track ahead consensu ahead estim
cowen compani
cowen compani compani report
confer call topic topic discuss amgen call may includ
aimovig commerci dynam access price market growth biosimilar
competit neulasta franchis fulphila udenyca on-going enbrel
patent litig sandoz potenti abil fend gener competit
sensipar via patent settlement parsabiv launch pipelin
particularli recent data releas regard kra inhibitor bite
calibr expect upcom data late
guid opex would in-lin cog expect
rel flat y/i expect spend increas earlier pipelin
product sg cost expect declin somewhat launch cost decreas
repurchas plan expect seen
ex- dutch tender
cowen compani
enbrel accord iqvia enbrel scrip q/q reflect
stabil drug posit rheum derm market despit long-term
demand price trend erod moder tracker show enbrel sale
like higher consensu estim slightli estim boost
season strong purchas pattern track toward
 exposur sale sale us total estim consensuscowentot revenu incom ep cowen
enbrel price dynam much less favor histor
sale higher expect y/i reflect trend
stabil volum price
note enbrel saw net price benefit base price increas well
improv contract new year beyond increasingli evid
franchis continu see eros estim enbrel sale
declin price pressur pick steam competitor gain
iqvia health cowen compani
su sandoz novarti patent infring argument heard
new jersey district court trial began septemb
close argument novemb anticip verdict recal
sandoz biosimilar etanercept erelzi garner fda approv august
launch stymi due much back forth two compani
procedur bpcia patent danc file suit sandoz infring
composit matter patent manufactur patent three use
patent also express high confid ip posit
continu make invest enbrel brand patent stand enbrel
would enjoy anoth year exclus patent expir
neupogen/neulasta cowen estim sale line consensu
 neulasta iqvia sale q/q y/i may
onpro on-bodi market share neulasta retain long-
act segment tracker use iqvia data project product sale project
vs consensu sale suggest neupogen/ neulasta
sale beat consensu
accord iqvia neulasta/neupogen sale y/i first two
month put sale track use tracker adjust
consensu call y/i declin sale
neulasta trend key focu model project neulasta
revenu coheru announc preliminari
unaudit net sale cowen specialti pharma team
project coheru cover ken cacciator achiev
udenyca revenu grow may fulphila
captur pegfilgrastim iqvia sale q/q udenyca captur
novartis/sandoz launch zarxio g-csf first biosimilar approv
fda zarxio launch discount join teva granix
g-csf competitor market short-act g-csf
zarxio follow granix footstep slowli steadili gain market
adopt iqvia data indic zarxio captur market share may
granix market share held steadi sale y/i
y/i april may show sign stabil octob pfizer
launch filgrastim biosimilar nivestym steepest discount yet
neupogen wac suggest neupogen declin could acceler
iqvia cowen compani
neulasta long-act g-csf product far bigger drug though
fulphila second bsufa date june approv somewhat surpris
came without adcom panel fda previous turn sever
biosimilar neulasta applic fulphila price discount wac compar
neulasta though believ neulasta fulphila similar
differ may fulphila captur pegfilgrastim market
though believ launch hamper suppli issu coheruss
biosimilar udenyca receiv fda june fda accept
resubmiss bla grant approv novemb udenyca launch
 januari discount wac neulastaon pariti mylan
biosimilar fulphila gain market share may
sandoz biosimilar applic receiv juli resubmit
applic april approv like pass-through code go
effect late set impact consensu estim call
y/i declin neulasta sale highlight continu competit
dynam market
meanwhil defens strategi hing larg on-bodi neulasta auto-
injector devic onpro launch earli on-bodi devic
steadili gain market share exit share neulasta market
note mani hospit system made consciou decis switch onpro
adjust nurs schedul protocol procedur result amgen
expect onpro market share somewhat sticki wake neulasta
biosimilar segment market like difficult biosimilar
aranesp cowen estim sale consensu
tracker use iqvia data project product sale project vs
consensu sale suggest sale consensu
aranesp sale stabl much larg part due increas
uptak dialysi center took advantag aranesp greater conveni
lower price forestal competit mircera recent competit
appear catch aranesp iqvia sale data good proxi
report sale sale y/i april may
epogen rais estim sale
consensu consensu expect y/i declin
tracker use iqvia data project product sale project vs
consensu sale suggest sale beat consensu
epogen year monopoli end roch launch mircera pegyl
erythropoietin roch subsequ sold right drug galenica freseniu
becom major custom convert nearli dialysi
patient mircera believ epogen sale stabil
iqvia confirm januari extend epogen suppli
agreement primari custom deal provid
price discount return long-term certainti demand
iqvia cowen compani
xgeva iqvia report sale april may y/i base
tracker sale track vs consensu impli
miss ex-u sale rel steadi
impli world-wide sale
in-lin consensu
prolia cowen estim sale consensu
tracker use iqvia data project product sale project vs
consensu sale scrip track higher
prolia xgeva monthli sale accord iqvia
iqvia cowen compani
repatha estim sale consensu
tracker use iqvia data project product sale project vs
consensu sale scrip track higher
repatha approv treatment hypercholesterolemia august
drug launch disappoint thu far physician interest prescrib
thwart reimburs pushback
februari juri upheld patent repatha case
regeneron win appeal compani ask judg anoth
injunct praluent may continu put tailwind behind
brand challeng futur outlook praluent manag state
earn call contract payor went faster expect
translat market share gain praluent
octob announc launch new ndc repatha list
price reduc out-of-pocket expens medicar part patient
regeneron follow suit march lower annual price praluent
optimist unit volum growth acceler afford improv
patient access expand despit sale growth y/i sale declin
repatha market share grow market split praluent
remain seen whether regn/sni abl revers trend
heel posit though mostli undifferenti data praluent outcom studi
odyssey well price concess on-going litig
provid tremend uncertainti futur outlook praluent
juli german court grant new injunct sny/regn praluent
germani plan enforc right injunct germani work
smooth transit patient praluent repatha estim
patient germani receiv praluent translat
view court decis major setback outlook praluent
increment posit germani prevail would
increment posit either own market territori
abl obtain injunct like receiv sizabl royalti payment
territori licens patent part settlement either way
occur posit also rais peak sale
repatha eu
iqvia cowen compani
aimovig cowen estim sale consensu
tracker use iqvia data project product sale project vs
consensu sale impli sale lower consensu scrip flat
compar last quarter key uncertainti price like reduc
heel sign new contract payor
sale sinc launch track impli iqvia
suggest aggress sampl aimovig expect sizeabl subset
prescript fill free drug
fda approv aimovig may prevent migrain adult
notabl inclus episod chronic migrain approv support
posit data sever phase ii phase clinic trial episod
chronic migrain aimovig price per year medicar part
specialti threshold price believ patient access
drug minim util manag criteria think price make sens
like reflect hesit part price aggress pushback
payor held back repatha commerci launch launch aimovig still rel
earli day prescript still repres free drug engag
success payor estim approv rate aimovig
reimburs util criteria expect requir patient fail
gener therapi physician attest
note earn call aimovig market leader
share new-to-brand prescript nbrx share benefit
strong market access condit earli phase product launch
major paid prescript reimburs near list price proport paid
versu free prescript increas end expect
net price aimovig stabil major coverag decis
made proport free prescript expect declin
iqvia cowen compani
competitor teva lilli anti-cgrp mab migrain teva
ajovi fremanezumab lilli emgal galcanezumab approv
fda septemb prevent treatment migrain adultsth
indic aimovigand price in-lin aimovig ajovi deliv via pre-fil
syring view disadvantag compar aimovig well lilli emgal
deliv via autoinjector monthli administr teva
product test quarterli basi mean patient could
inject ajovi three time everi three month patient might find
appeal aimovig nearli five-month head start howev well-receiv
autoinjector place current competit advantag emgal see
strong uptak gain signific market share aimovig base iqvia
scrip aimovig end q/q prescript share ajovi
q/q share emgal q/q
kyproli cowen estim sale consensu vs
tracker use iqvia data project product sale project vs
consensu sale
concern rare cv event competit product includ takeda velcad
ninlaro limit kyproliss growth potenti
sensipar/parsabiv tracker use iqvia data project product sale project
vs consensu sale scrip track lower
cowen estim sensipar sale consensu vs
estim assum on-going gener competit henc reli iqvia
rx accur given captur gener entri
market point
cowen estim parsabiv sale line consensu vs
tracker use iqvia data project product sale project
vs consensu sale
januari sensipar move part reimburs
part system alongsid parsabiv sensipar parsabiv transit
esrd bundl
sign settlement agreement gener compani approv
anda teva gain fda approv gener sensipar late decemb began
briefli sell market settl delay sale
anoth gener compani pend anda optimist
near approv could sign addit settlement
sensipar remain protect formul patent would expect
sensipar gener launch per negoti settlement prolong
exclus period could benefici amgen effort convert patient
sensipar parsabiv
parsabiv launch januari strong start sale
drug superior
toler may allow long-term success
nplate cowen estim sale consensu
tracker use iqvia data project product sale project vs
consensu sale
nplate fairli matur franchis benefit price increas iqvia data
indic y/i sale growth april may trend somewhat
guidanc model project total revenu y/i non-
gaap ep y/i consensu call total revenu
y/i non-gaap ep y/i consensu revenu estim appear
conserv maintain much financi flexibl particular abil
control cost repurchas share therefor would expect top
bottom line consensu
look updat litig vs sny/regn updat
potenti settlement gener sensipar maker possibl district court decis
enbrel patent infring suit sandoz updat pipelin program includ
variou bite inhibitor inhibitor
thesi like fundament due diversifi product
mix biolog franchis durabl protect product innov pipelin
tight control opex aggress cash return sharehold see near-term
risk enbrel sensipar gener challeng new product launch
includ aimovig biosimilar provid new growth prospect legaci
franchis declin opinion continu provid sustain growth
navig turbul water legaci franchis erod meantim
tezepelumab earli stage oncolog pipelin gain visibl shore
confid long term prospect
cowen compani consensu thomson reuter
invest thesi amicu develop improv therapi ultra-orphan
includ oral pharmaco-chaperon galafold fabri approv launch
europ japan us galafold ex-u momentum remain sound
us launch impress rapid earli uptak amicuss pipelin also
combo at-gaa pomp diseas candid recent grant
breakthrough design produc encourag function data nave
switch pomp patient excel safeti suggest could becom best-in-
class pomp treatment eu us regul align upon phase trial design
discourag compani submit condit file base phase
data alon recent expand pipelin lsd gene therapi two
alreadi clinic batten diseas updat data
program expect mid-year could constitut major catalyst share
patient releas
ex-u galafold launch track expect us launch continu acceler
estim galafold sale vs consensu report
galafold sale vs consensu slight growth q/q
mostli driven ex-u sale prescript trend matur still
grow us script impact limit season well
initi averag time shipment start form prf start contribut
significantli time prf shipment shrink fx headwind also contribut
small miss still amicu emphat reiter guidanc
would repres y/i growth
galafold approv across major market eu australia canada israel
switzerland south korea japan us price reimburs secur
individu countri continu think us opportun larger consensu
think earli us launch number provid earli januari speak volum
high demand drug think high demand unsurpris given
galafold market europ year gener excel
real-world experi sourc growth acceler us includ us
regul allow compani market directli patient vs eu higher
number diagnos untreat fabri patient eu newborn
screen like acceler diagnost rate newborn famili member
typic diagnos amen mutat
recal nch gene therapi construct current test single-arm
phase clinic investig studi twelv patient enrol
treat far singl intrathec administr vg
amicu believ like optim dose proven safe far
time program acquisit septemb encourag see
efficaci observ patient match sibl pair mutat
follow month two-year follow-up hamburg score motor
languag subscal data show symptom diseas progress younger
patient treat year age limit progress follow
potenti diseas stabil older sibl treat year age follow-up
data patient well data least half patient
present may key catalyst
pomp soc natur histori data also year mayb octob
possibl toplin sooner amicu remain track releas result on-going
retrospect natur histori studi approxim pomp patient
treat soc ert provid meaning context open-label
switch result seen far at-gaa includ data given fda
recent decis grant breakthrough design at-gaa pomp inform
comparison retrospect data expect natur histori cohort
clearli highlight superior amicu candid compar soc ert
cowen compani consensu thomson reuter
bold invest thesi audent bold gene therapi compani focus
develop treatment monogen orphan diseas primarili affect young
patient compani lead asset treatment xlmtm
addit program crigler-najjar syndrom pomp diseas
phase data show signific consist sustain even
increas improv neuromuscular motor respiratori function
observ patient treat notabl efficaci high dose low
dose compar assess safeti
accept view updat grow alreadi strong bodi data support
potenti confer transform clinic benefit xlmtm also view
bold preclin gene therapi program dmd myoton dystrophi
asgct bold present addit phase data xlmtm aspiro
trial addit follow-up cohort patient week show continu
durabl improv across function measur includ patient
becom ventil independ new data high dose cohort highli
encourag although addit readili visibl advantag increas
dose nevertheless bold indic lean toward file high-dos
potenti bla file data indic effect patient regardless
dose appar age function improv motor mileston
remain consist time sinc profoundli
increas qualiti life xlmtm patient
sinc last data updat anoth patient high-dos patient experienc troponin
lft elev previous observ one patient resolv steroid
mild subclin platelet declin also quickli resolv sequela
recurr anoth patient week cholestat event detect bilirubin
increas deem possibl drug relat despit previou cholestat event
sever prior hyperbilirubinemia view safeti event
barrier approv
bold decid final commerci dose like dose believ
commun fda later year determin final registr
path bla submiss believ anoth fda discuss result final
agenc sign-off clear regulatori path announc recal
bold intend dose expans cohort addit patient high
dose hope see data origin patient well
first/parti data expans cohort next data updat expect
octob
pomp safeti issu like address per success non-glp nhp tox
studi new construct ind slate
audent program pomp diseas potenti address
shortcom pomp ert like low gaa uptak target tissu
immunogen bold announc track success complet
non-glp nhp preclin studi tox signal file ind
complet two pend studi on-going parallel nhp glp-toxic
studi dose ranging/select studi mice model
cowen compani street consensu beigen
sale celgen product revlimid vidaza abraxan
total revenu includ sale celgen product china
collabor revenu
expect gaap ep line street consensu
estim due higher expens
model updat rais estim rais
 estim new ep estim
beigen report strong driven driven upsid chines sale q/q
lower opex q/q upsid driven rebound weak
expect season fluctuat sale expens
q/q larg due reduct busi develop relat expens
higher opex driven higher expens expens expect
slightli higher
potenti zanubrutinib approv r/r mcl r/r cll china prioriti review
potenti tislelizumab approv chl china potenti china pivot phase ii data
nda file zanubrutinib wm china
beigen lead asset zanubrutinib offer differenti profil abbv/jnj
imbruvica market lead btk inhibitor zanubrutinib good oral bioavail
high specif btk deep respons favor safeti profil beigen
second asset tislelizumab engin antibodi fix
complement henc somewhat differenti opdivo keytruda june
beigen announc termin tislelizumab collabor celgen
upon celgen paid up-front payment celgen critic
support global phase studi anticip approv chl china
small market segment import strateg mileston compani
beigen third asset pamiparib highli select parp inhibitor strong parp
trap activ top-lin data china pivot phase ii trial ovarian cancer
read late earli drug global phase gastric
cancer offer favor risk/reward profil anticip data
juli beigen sign collabor agreement celgen obtain right
abraxan revlimid vidaza china beigen book sale pay
transfer price reward celgen busi profit
ww sale like come consensu
scrip trend suggest sale consensu
anticip sale flat slightli
analysi suggest world-wide interferon sale line
estim though perhap touch
sale like come consensu
analysi patient trend suggest estim
consensu readili achiev
sale trend suggest revenu consensu
cowen compani bloomberg consensu
anticip upsid spinraza strong sale
across franchis could drive total revenu ahead
estim appear achiev cost save
realiz aducanumab failur
report date juli confer call estimate within
earn summari confer call topic expect post revenu
least in-lin consensu beat like base strong perform
spinraza sever ms product franchis prescript trend
biogen multipl sclerosi franchis solid though wholesal stock pattern
difficult predict ms franchis revenu would appear track least
line consensu like also updat yearli financi guidanc
call custom expect cost save failur aducanumab like
lead increas ep guidanc financi appear solid biogen
longer term growth prospect less clear competit sma ms draw
near predominantli high risk program pipelin expect investor focu
call larg pipelin strategi thought around
impend competit spinraza sma nvss recent approv
zolgensma gene therapi roche/ptc risdiplam expect regulatori file
abil defend tecfidera ip
tecfidera tecfidera shortcom associ pml observ
breakthrough diseas difficulti complianc gi toler problem led
modest share deterior trend halt tecfidera
held ms market past sever year figur exclud
infus drug ocrevu tysabri
tecfidera estim q/q y/i includ
 revenu q/q y/i ex-u revenu q/q y/i
consensu revenu q/q y/i includ
 q/q y/i ex-u q/q y/i
prescript trend tecfidera solid appear tecfidera
weather launch ocrevu iqvia-report trx q/q tecfidera
market share remain stabl level end
tecfidera nrx grew q/q result nrx market share term
overal market iqvia report total ms prescript volum increas q/q
follow decreas q/q nonetheless note short
term trend ms market mislead iqvia retrospect
acknowledg data error impact ms market multipl occas past
report tecfidera sale q/q y/i though
manag note report revenu includ decreas channel inventori
compar increas therefor end user
demand approxim factor increas q/q would impli
 tecfidera sale estim consensu
re-stock channel could contribut addit upsid
launch tecfidera europ drug perform
reason well term patient drug lower ex-u price issu ex-
 volum growth also often obscur combin fx headwind
parallel trade dynam inventori fluctuat report ex-u
tecfidera sale q/q y/i tecfidera japanes launch began
late decemb cours tecfidera saw double-digit volum
increas europ japan y/i absenc major new territori
estim q/q y/i consensu q/q y/i
impli modest q/q declin due lumpi ex-u order pattern though
limit visibl ex-u sale appear reason
analysi suggest world-wide tecfidera revenu
consensu estim
partner submit nda vumer hope
pathway approv applic assign pdufa date
submiss includ data singl arm two-year safeti studi rrm
patient data cut june pharmacokinet bridg analysi tecfidera
clinic studi shown equival efficaci tecfidera howev importantli
much improv toler discontinu rate due gi within
first month treatment seriou gi
headto-head comparison studi vs tecfidera gi toler yield data
data continu suggest improv gi profil vumer could help
biib franchis recaptur share importantli vumer ip protect thought
approxim year longer tecfidera therefor could provid
valuabl extens ms franchis well
avonex plegridi avonex/plegridi interferon franchis cede share
oral ms drug sever year expect trend continu
interferon sale estim q/q y/i consensu
q/q y/i estim y/i
y/i ex-u estim q/q y/i
report interferon sale q/q y/i
consist q/q y/i avonex q/q
y/i plegridi note report revenu impact
decreas channel inventori approxim impli end user demand
approxim
total interferon trx increas q/q accord iqvia suggest
 interferon sale track toward end user demand
consensu
ex-u avonex sale also hurt competit oral biogen
report ex-u avonex sale q/q y/i ex-u plegridi
sale q/q y/i hedg strategi shield approxim
ex-u avonex plegridi sale month advanc therefor
anticip littl fx impact q/q basi assum abnorm order expect
quarterli ex-u avonex sale rang consist
estim street consensu moreov previou quarter
report ex-u plegridi sale expect level revenu
continu report ex-u plegridi sale
togeth figur suggest world-wide interferon franchis sale
estim though consensu
 market ms therapi weekli prescript trend
iqvia cowen compani
tysabri tysabri sale essenti flat sever year price
increas offset volum declin howev launch ocrevu drove
increas tysabri discontinu particularli common jcv tysabri
patient past five quarter report
tysabri estim q/q y/i consensu
report tysabri sale q/q y/i though
note report revenu affect decreas channel
inventori impli end-us demand iqvia indic tysabri sale
decreas y/i basi increas q/q basi first two
month quarter prescript trend impli tysabri end user demand
would increas impli revenu
ex-u sale q/q y/i ocrevu receiv full eu
approv januari howev take time achiev broad
reimburs anticip ocrevu begin grow impact tysabri
sale therefor suspect ex-u tysabri revenu would
therefor analysi suggest ww tysabri sale
consensu
initi phase iiib studi examin extend interv dose regimen
tysabri associ efficaci potenti reduct pml
antibodi revenu demand antibodi continu grow year
rituxan launch record q/q y/i
revenu rituxan/gazyva joint ventur non-ocrevu royalti iqvia sale
rituxan/gazyva first two month q/q basi
y/i therefor anticip rituxan/gazyva jv revenu non-ocrevu
royalti
iqvia cowen compani
entitl royalti ocrevu net sale
disclos royalti rate trigger ocrevu annual sale exceed
given signific royalti estim entitl nearli
ocrevu econom valu roch report strong ocrevu sale
launch onto market furthermor roch report ocrevu
patient ppm market ocrevu first drug label ppm
therefor would appear ocrevuss avail grow ms market
provid ppm patient approv therapi
roch report ocrevu sale chf iqvia report sale
first two month q/q would impli chf
similar usd sale therefor assum royalti rate sale
due possibl sale tier royalti rate
sale anticip record royalti
 ocrevu sale ocrevu approv ema januari
reimburs advanc eu countri howev receiv royalti
ex-u ocrevu sale roch report eu intern ocrevu
sale chf lead royalti conserv
estim contribut togeth expect recogn
approxim world-wide ocrevu royalti
total anticip could record collabor revenu
would rel line well
competit increas consult continu indic adopt
spinraza much enthusiasm sinc decemb approv especi type
ii sma patient major barrier adopt consult report
vast major diagnos patient current spinraza therapi
nonetheless competit increas nvss sma gene therapi zolgensma fda
approv current indic sma infant age
expect modest impact spinraza revenu
direct competit like come roch risdiplam
similar mechan spinraza expect secur similarli broad label roch
expect file fda approv risdiplam
spinraza estim q/q y/i
establish spinraza wac price inject
year year thereaft spinraza launch continu strong
patient commerci therapi world-wide end biogen
report new patient start compar
overal new patient start continu slow
increas adult therapi compar
new start adult outsid patient growth remain
strong ex-u patient therapi q/q
 spinraza sale report spinraza sale
q/q y/i patient therapi new patient start
decreas averag number dose per patient
estim infant pediatr patient adult
year older therapi
assum patient start evenli distribut throughout quarter spinraza
induct mainten dose regimen lead record dose revenu
per patient start first financi report quarter dose revenu
second report quarter dose revenu third report quarter
dose revenu subsequ quarter therefor base histor figur
patient start sinc launch lead dose revenu
assum number new-pati start drop across new
exist spinraza patient anticip administ dose
spinraza assum gross-to-net adjust would
repres sale base histor patient start actual
patient number present appear though discontinu rate
would yield quarterli revenu
ex-u spinraza sale spinraza approv eu june
demonstr strong sale growth sale return strong
growth trajectori follow lighter outsid spinraza
reimburs countri achiev regulatori approv countri
ex-u commerci patient volum grew end
ex-u commerci patient assum ex-u commerci patient
mainten phase patient requir mainten
dose would repres dose averag price less
estim net price would gener revenu
mainten dose continu commerci spinraza patient
averag number new ex-u commerci patient increas
past four quarter number highlight taiwan
china hong kong lat brazil canada turkey key market ex-u growth
expect patient number continu expand ww although
mayb rate seen therefor think reason ex-u
patient would start commerci therapi
expand access program appear use larg program grant
access spinraza load dose month lead formal reimburs
within countri patient eap program continu
transit patient commerci therapi assum patient
transit eap commerci therapi patient would util
dose spinraza averag price would translat
revenu eap patient transit onto commerci therapi
would leav addit patient start commerci spinraza
sinc patient pass eap like requir full
cours load dose assum averag patient complet load dose
patient would gener dose spinraza
averag price would repres revenu would
lead total ex-u spinraza sale assum discontinu
rate ex-u sale would
thu analysi impli world-wide spinraza sale ahead
consensu even spinraza uptak slow appreci
would appear estim consensu readili
eu biosimilar benepali biosimilar version pfizer/amgen enbrel develop
samsung bioepi jv samsung biolog benepali approv
ema europ launch samsung bioepi also receiv ema
approv fliximab biosimilar remicad juli ema approv imraldi
biosimilar humira though launch imraldi octob
follow april patent settlement hold commerci right
benepali fliximab imraldi europ book product-rel sale
expens
report q/q y/i biosimilar revenu
benepali market nearli year fliximab two half suspect
neither wit major acceler imraldi launch octob
anticip take sever month european govern
request begin execut tender offer sale encourag
expect modest increas sale quarter therefor anticip
biogen eu biosimilar revenu could climb hope
acceler growth imraldi begin penetr eu market
updat yearli guidanc call customari expect
adjust yearli guidanc upcom call follow discontinu
aducanumab phase program indic approxim
cost save would realiz includ reduc oper
expens follow closeout cost
anticip cost save partial off-set increas invest
associ nightstar transact expens sg
busi develop non-gaap ep estim
reflect expect save aducanumab failur current guidanc
non-gaap ep
thesi believ biogen commerci franchis capabl gener low-
single-digit top- bottom-lin growth project period
revenu compound-annual-growth-rate ep compound-annual-growth-rate trade
dcf-base price target therefor continu look somewhat
under-valued nonetheless competit launch spinraza decis
tecfidera ipr anticip two largest franchis account
project revenu face challeng given potenti impact
 either stumbl intermedi long term prospect growth less
certain confid anyth pipelin capabl
re-acceler revenu earn next sever year suffici drive
major re-rat stock though program address major unmet
need sizabl market consid mani high risk underli diseas
mechan poorli understood model includ meaning revenu
contribut pipelin opinion signific pipelin success busi
develop need stave fear spinraza competit tecfidera
patent cliff return favor
look potenti data nightstar ph studi nsf-fpgr
xlrp potenti initi data nightstar ph ii/iii studi nsf-fpgr xlrp
updat biogen plan biosimilar jv follow exercis option
potenti result head-to-head toler studi vumer tecfidera
potenti updat regard vumer regulatori process expect launch
addit busi develop deal augment pipelin
cowen compani consensu bloomberg
quarterli sale lumpi estim appear
estim call modest growth q/q think
estim achiev despit patient convert
visibl low estim consensu look achiev
assum modest growth
q/q sale perform difficult predict base
time revenu recognit
expect remain modest brineura continu
process find patient
palynziq launch thu far encourag
disclos patient number impli estim consensu
achiev
manag project total revenu
thu estim yearli revenu appear
report date august hold cc et
earn summari biomarin note steadi consist rate growth
number patient use key product disrupt anticip
continu solid perform bmrn base busi quarter
anticip investor keen monitor palynziq launch analysi
suggest estim consensu achiev even notabl
progress bmrn late stage program valrox file fda approv
vosoritid phase data anticip toward market bmrn solid
base busi break profit pipelin appear capabl drive
mid-teen revenu growth well next decad continu consid
vimizim project vimizim sale q/q y/i vimizim
consensu alway visibl vimizim quarterli sale low
report revenu heavili influenc larg lumpi order ex-u
countri report world-wide revenu y/i
number patient therapi grew y/i estim y/i
consensu y/i reflect assumpt consist revenu growth
level somewhat lower patient growth moreov price increas taken
help report revenu thu visibl low estim
consensu appear achiev
kuvan kuvan estim q/q y/i consensu
q/q y/i estim consensu assum on-going
launch palynziq increasingli cannib kuvan progress
bit rebound kuvan follow season soft
report revenu q/q impact typic insur
disrupt come turn calendar revenu also aid
price increas taken therefor estim consensu appear
achiev despit like headwind patient switch kuvan palynziq
manag guid kuvan sale versu report
revenu
biomarin reach settlement pharma allow kuvan gener enter
 market follow settlement dr reddi kuvan
gener expect biomarin abl transfer
larg percentag kuvan patient palynziq earli launch
palynziq continu promis launch palynziq estim
q/q consensu q/q palynziq approv
may launch encourag start march total
uniqu clinic pku clinic one patient enrol
patient commerci reimburs palynziq
patient commerci palynziq februari addit biomarin indic
patient enrol treatment center wait receiv
first commerci dose palynziq total patient enrol
begin palynziq approxim adult patient treatment pku clinic
 patient alreadi initi therapi clinic
program formerli palynziq-na call manag
indic naiv patient come previous kuvan
patient follow-up remain limit manag indic rate
discontinu low singl digit remain small lower seen clinic
biomarin price palynziq flat wholesal acquisit cost wac
biomarin estim averag patient requir unit per patient per day
mainten dose averag annual net cost therapi typic patient
patient palynziq start
clinic program assum mainten dose patient
could expect gener revenu palynziq-
nave patient would like still titrat phase revenu less certain
one assum averag half-dos would impli
gener revenu addit februari march
ad new patient commerci therapi assum pace continu
new patient would expect ad commerci therapi
assum patient averag quarter dose would gener
revenu altogeth analysi suggest palynziq revenu ahead
consensu therefor estim consensu appear
may palynziq receiv eu approv palynziq treatment pku
patient age year older eu drug approv age year
older instead year includ dose wherea
mg dose approv manag indic
consequ addit data cohort patient time
regulatori submiss eu manag indic sale palynziq ex-
 like modest begin ramp
manag indic palynziq could yield annual revenu
biomarin indic europ middl east africa
adult young adult patient want activ manag diseas
compani achiev penetr garner averag revenu
patient per year palynziq would achiev revenu without account
uptak latin america asia
biomarin expect file cta ind bmn gene therapi pku
naglazym sale estim q/q y/i
consensu q/q y/i naglazym sale also heavili
influenc larg order ex-u territori visibl low nonetheless
estim consensu appear achiev naglazym revenu grew
y/i number patient therapi grew y/i therefor estim
consensu assum y/i growth somewhat pace increas
patient therapi though naglazym quarterli revenu lumpi continu
grow steadili year year despit fact market
decad midpoint guidanc impli y/i growth
aldurazym project biomarin report aldurazym revenu
q/q y/i stem aldurazym end user sale
consensu call biomarin record aldurazym revenu aldurazym
revenu recogn time transfer sanofi/genzym rather time
product sold genzym custom therefor quarterli revenu lumpi
difficult predict
brineura brineura launch continu gradual biomarin work identifi
patient secur reimburs ex-u territori brineura produc
revenu impli approx patient therapi consist
estim q/q consensu y/i
project addit net patient appear reason
disclos top-lin data ph i/ii studi valrox hemophilia may
subsequ present isth juli data cut-off date april
three year follow-up patient dose vg/kg dose
cohort saw median fviii level iu/dl measur chromogen assay
iu/dl one year follow-up iu/ dl two year
mean fviii level iu/dl year respect
though factor level decreas year appear reach plateau
dose cohort treat prophylact fviii median annual
bleed rate abr continu three year follow also year
mean abr year respect data
compar pre-valrox treatment abr median mean repres
reduct mean abr overal patient bleed-fre
year respect compar baselin median annual fviii infus
also year respect compar treatment mean
annual fviii infus year respect compar
pre-treat repres reduct mean fviii usag addit
biomarin provid statist analysi exist data project valrox
treatment durat least year curv use slope fviii level
declin y/i cohort ph i/ii studi initi fviii level gener
ph extrapol curv would take approxim year
mean fviii level drift iu/ dl level manag indic clinic
provid initi data ph studi valrox patient dose vg/kg
april cutoff date patient evalu achiev fviii level
iu/dl threshold establish fda week
data cutoff time addit patient cross threshold three subject
remain evalu disclos fda criteria acceler
approv requir patient achiev fviii level iu/dl therefor
interim phase data met criteria necessari acceler file
median fviii level week time frame iu/dl mean
iu/dl notabl level seen phase i/ii studi similar time
point estim median mean abr patient evalu
data cut-off respect repres reduct
baselin furthermor reduct median annual fviii usag
reduct mean fviii usag week manag indic
patient fail achiev fviii level iu/dl compani
evalu potenti opportun decreas failur rate includ potenti
dose escal prophylact steroid
lead regulatori file valrox achiev pre-specifi
criteria acceler approv file patient need achiev fviii level
iu/dl threshold set fda patient remain
evalu biomarin fda ema review ph i/ii ph data
gener well compon necessari regulatori submiss
base discuss recent announc intent file regulatori
approv eu fda design valrox
breakthrough therapi would seem like garner prioriti review impli
key remain question place valrox occupi treatment
paradigm particularli light establish standard care prospect
innov gene therapi futur ph proport
patient respond factor level iu/dl evalu
higher expect median factor level iu/dl somewhat
would suggest phase i/ii data though neither
issu would appear like impact valrox approv would potenti
factor commerci adopt past physician consult suggest
ideal gene therapi would get patient normal rang modest
interpati variabl non-respond base limit interim phase
data valrox profil approach ideal though fall bit short particularli
percentag non-respond therefor valrox place treatment paradigm
yet defin remain determin proport patient rapid
adopt versu proport may wait gene therapi improv
profil improv profil valrox follow dosing/manufactur
adjust valrox launch trajectori uncertain littl question
hem larg market biomarin estim overal hemophilia
patient territori noram latam eumea apac north america
alon thu even modest penetr price point around would repres
signific revenu sale could achiev everi adult patient
treat therefor valrox soon becom growth driver biomarin
vosoritid phase data anticip phase studi vosoritid
children achondroplasia fulli enrol top-lin data expect
intern phase trial random placebo control studi
long-term open label extens primari endpoint annual growth veloc
patient age consist phase ii popul
invest thesi biomarin leader develop therapi
orphan diseas discount cash flow analys suggest biomarin base busi
worth vimizim worth addit project
brineura revenu potenti dcf analysi suggest could
worth biomarin dcf analysi suggest vosoritid
achondroplasia could worth notabl pipelin program
includ valuat analysi includ valrox gene therapi hemophilia
two pivot phase trial tralesinidas alfa mp earli
stage potenti pivot phase ii project biomarin revenu increas
drive biomarin profit expect biomarin
share outperform market next month solid perform
market product continu launch vimizim brineura palynziq
progress program pivot develop approach regulatori approv
look continu launch metric patient treat commerci
palynziq enrol complet bmn pivot high dose cohort potenti decis
whether submit ind bmn friedreich ataxia launch palynziq
eu potenti file ind bmn pku
cowen vs street consensu estim celg
track consensu
track consensu
track consensu
track consensu
track in-lin consensu
track consensu
guidanc
guidanc
guidanc
guidanc
guidanc
guidanc
cowen compani street consensu provid celgen excl option expens up-front collabor payment sever addit item
earn summari celgen re-affirmed financi guidanc
earn releas guidanc found tabl celgen
re-affirmed goal total revenu non-gaap ep greater
compani continu advanc late-stag asset approv
expect revenu ahead expect vs ep also
ahead expect celgen reaffirm guidanc total revenu
adjust dilut ep
cowen compani
cowen compani thomson
revlimid cowen estim sale consensu vs
tracker use iqvia data project product sale project
vs consensu sale suggest sale
consensu scrip track flat compar higher
price increas januari
abraxan cowen estim sale line consensu vs
tracker project vs consensu sale suggest
 sale beat consensu product saw price increas
pomalyst cowen estim sale consensu vs
tracker project vs consensu sale
suggest sale consensu scrip track higher
pomalyst price rais januari
vidaza cowen estim ww sale consensu
tracker project us sale vs consensu ww sale
suggest sale consensu
thalomid scrip track lower lower
estim slightli consensu ww sale y/i
otezla cowen estim sale consensu
tracker project vs consensu sale suggest sale
consensu scrip track higher higher
price rais januari
anticip stock movement durat celg time list
public compani driven financi recal januari market
perform cover steve scala announc intent acquir celgen cash
stock transact ev celg sharehold receiv one bm
share cash per celg share addit celg sharehold receiv
conting valu right cvr celg share whose valu depend futur
regulatori mileston holder entitl one-tim payment
ozanimod liso-cel approv decemb
approv march acquisit origin expect close
sharehold vote april approv deal
howev due anti-competit concern feder trade commiss ftc
requir divestitur otezla approv merger delay close deal
earli also extend expir date celgen note
regulatori pipelin highlight nda fedratinib treatment
myelofibrosi submit march celgen announc fda
accept compani nda grant prioriti review fda set action date
septemb celgen also plan evalu fedratinib combin
luspatercept eu submiss plan year-end
celgen resubmit nda ozanimod rm march enrol
phase north studi ozanimod uc complet april
enrol phase crohn studi on-going
regulatori submiss luspatercept md beta-thalassemia fda
ema complet april pdufa date beta thal earli dec md
april eu review expect complet late
initi partial data transcend studi liso-cel report
eha show promis earli efficaci safeti data dlbcl regulatori
submiss plan anticip final data transcend
cll studi also report promis earli efficaci safeti data cll icml
pivot karmma data rrmm expect potenti
regulatori file late
revlimid like protect march celgen settl revlimid
patent litig alvogen celgen agre provid alvogen licens use
celgen patent manufactur sell revlimid volume-limit manner
look look buyer otezla view
divestitur complet facilit deal close
bloomberg cowen compani
though accuraci iqvia data unclear
suggest estim consensu
growth dynavax continu make progress launch heplisav
quarterli sale grew q/q project sale
q/q consensu q/q dynavax manag note
heplisav revenu like lumpi earli compani remain
midst work formulari reimburs process target
custom number account place order still begin grow
manag remain optimist meaning growth state
expect heplisav cash flow posit end year specif
manag guid yearli sale greater
earli heplisav launch dynavax suggest publicli avail prescript
sale data unlik accur howev iqvia-report sale data align
close dynavax report revenu past quarter
dynavax report sale heplisav
respect time period iqvia report quarterli heplisav sale
respect
first two month iqvia report sale q/q
assum similar q/q growth june heplisav revenu would ahead
estim consensu admittedli month month order pattern like
lumpi nonetheless even june sale similar may heplisav sale
would in-lin consensu thu avail iqvia sale data impli
consensu estim appear achiev
one coven dynavax loan agreement crg requir heplisav
achiev revenu revenu annual pace
investor grow nervou chanc could violat
coven investor take littl comfort fact dvax guidanc
heplisav revenu suspect healthi growth could help
allevi fear particularli sale put revenu close
superior efficaci fewer dose caregiv attract heplisav
profil enthusiast option patient base earli
feedback dynavax remain convinc heplisav becom standard care
hbv vaccin time dynavax make encourag progress work
reimburs process target custom previous note addit
insur coverag purchas requir committe approv
contract switch heplisav made compani
quarterli call target account made heplisav avail
order repres target adult hepat market manag also
indic individu custom purchas heplisav sinc
launch dose sold date custom
reorder least day overal top target custom
order heplisav purchas contract sign top retail
pharmaci top integr deliveri network made heplisav
avail order furthermor dod access point made heplisav
exclus hepat vaccin new recruit
expect heplisav uptak continu gradual due
consider physician gain addit comfort vaccin
enrol complet heplisav post-approv studi could provid boost
sale studi expect complet enrol accord
heplisav fda approv letter interim analysi report due fda
studi complet trial
conduct kaiser permanent southern california receiv heplisav free
charg enrol heplisav patient given larg number hbv
vaccin experi heplisav believ kaiser permanent
heplisav estim assum share hepat vaccin
market without allow market expans new popul diabet
think estim reason expect heplisav becom market-
lead hbv vaccin time consult find particularli compel
heplisav consist produc higher rate engerix-b consult also
impress heplisav reduc number requir inject offic visit
say difficult get mani patient return offic third shot
month six older vaccin requir dynavax indic
patient miss third dose think heplisav regimen dose month
much conveni lead better complianc henc protect
estim peak heplisav sale see vaccin support valuat
dcf basi substanti stock
trade price hope heplisav launch continu gain steam
investor gain confid vaccin potenti
dynavax announc march ema accept heplisav review
final decis approv vaccin eu anticip
what come dynavax present updat data clinic studi
agonist present support therapi potenti
benefit use combin inhibit keytruda patient pd-
nave experienc melanoma metastat head neck cancer
perhap intrigu orr seen nave metastat melanoma
patient singl arm studi difficult interpret orr encourag
respons rate monotherapi produc pivot trial
nonetheless dynavax disclos invest develop sd-
addit studi conduct partner found
continu believ littl valu receiv
meaning up-front mileston partnership
success advanc would repres upsid project
thesi dynavax heplisav hbv vaccin shown
effect conveni current market hbv vaccin number
phase trial launch januari heplisav recent phase
subject trial primari efficaci endpoint seroprotect
rate within subset patient type diabet heplisav-b gener
statist signific superior maxim compar engerix-
 consult expect superior seroprotect requir fewer
inject allow heplisav captur signific share ww market
adult monoval hbv vaccin dynavax search licens develop
partner class cpg agonist phase iii-readi
nave metastat melanoma gener interest data patient
popul well think under-valued base potenti heplisav-b
hbv vaccin market
look potenti announc commerci
develop partner continu execut heplisav commerci launch
enrol complet heplilsav post-approv studi
street consensu bloomberg sourc cowen compani
revenu weight toward approxim per manag
commentari model slightli heavili toward guidanc
earn summari indic revenu guid
back-end weight approxim split part
due time deliveri biothrax nuthrax product strateg
nation stockpil consist previou year model slightli heavier
weight split first full year sale newli acquir product narcan
vaxchora vivotif also includ revenu guidanc total
market product model revenu anthrax vaccin franchis
revenu estim in-lin manag
guidanc due lumpi revenu recognit year
expect compani earn call focu progress nuthrax
manufactur phase develop updat follow-on contract
negoti driver narcan mix retail public
interest market detail key driver financi guidanc pipelin
updat addit product licens discuss
steadi biothrax sale compani portfolio expand product
follow paxvax adapt pharma acquisit biothrax still constitut
largest portion ebss revenu singl product despit lumpi due revenu
recognit time biothrax revenu
estim remain key profit driver biothrax
higher margin provid biothrax center diseas control
prevent cdc biomed advanc research develop author
barda two contract cdc contract sign decemb valu
call deliveri million dose strateg nation
stockpil sn septemb price per biothrax dose
subject annual price escal remaind contract
addit march manag announc barda award contract
call worth addit biothrax period month
plan deliv approxim nine million dose biothrax sn
thu yearli project biothrax sale fairli straightforward
manag emphas time biothrax deliveri contract
difficult predict henc lumpi evid quarterli basi though
annual shipment predict
import growth driver septemb award
competit contract allow develop nuthrax deliv
initi dose vaccin sn follow emerg use author
eua pre-approv sinc appli eua decemb may
announc notifi barda begin procur nuthtrax sn
compani plan deliv nuthrax contract includ option
govern procur dose nuthrax potenti valu
revenu estim includ nuthrax dose potenti
post-market commit valu henc govern exercis
option contract valu current model us govern
exercis option believ investor expect well may
also expect procur continu beyond horizon price structur
nuthrax tier step-up fda approv nuthrax
also volume-bas price tier estim initi per-dos cost nuthrax
step-up occur potenti fda approv
time order nuthrax contract like lumpi year year
downsid risk us govern may choos exercis
procur option may take longer anticip current develop
valid nuthrax releas assay initi phase trial march
studi anticip enrol adult us studi site particip
random studi cohort stratifi site cohort receiv
vaccin consecut manufactur lot nuthrax
cohort compar arm patient receiv biothrax studi
anticip complet novemb
make use build capac ebss new biothrax contract use bldg
full capac biothrax dose per year result anticip
manag util addit capac produc biolog manag
maintain small amount biothrax product build work
transit manufactur product sole build biothrax
nuthrax build use program includ expans
compani busi manag hope leverag german approv
build attain contract nato govern april
biothrax grant market author five addit european
countri itali poland franc netherland mutual
recognit procedur base germani europ biothrax
market bacithrax howev previous indic foreign govern
contract difficult achiev target total sale outsid
grow non-biothrax busi manag activ engag
expand biodefens product portfolio acquisit acquir
right militari grade auto injector award depart
state contract manufactur deliv addit trobigard train auto-
injector work european supplier modestli expand output
identifi supplier match demand auto injector requir
fda approv prior use manag anticip initi two human
factor studi near-term plan develop addit auto-injector well
contract medic cbrn defens consortium mcdc juli
announc award mcdc contract fund
develop novel multi-drug auto-injector nerv agent antidot deliveri
octob close acquisit live small pox vaccin
approxim sale potenti start deal emerg
also acquir cdc contract mm remain valu set expir
septemb receiv fda approv make canton
facil began deliveri cdc late expect govern demand
somewhat uncertain precis revenu beyond
depend follow-on contract negoti deliveri current contract
complet posit govern establish stockpil
product tend maintain note competitor bavarian nordic develop
smallpox vaccin imvamun produc posit phase data februari
though drug yet fda approv expect approv barda
award pre-approv procur contract imvamun includ dose
older liquid-frozen formul approxim dose freeze-dri
formul howev bavarian nordic target inact vaccin patient
sever immunodefici activ vaccin like
otherwis contraind confid govern want activ
vaccin well model us sale per year pend addit
clariti follow-on contract
addit octob close acquisit raxibacumab
monoclon antibodi treatment prophylaxi inhal anthrax gsk
total consider deal emerg acquir intellectu
properti right raxibacumab remaind exist contract
biomed advanc research develop author barda suppli
raxibacumab strateg nation stockpil sn residu valu
model raxibacumab sale ramp
octob acquir privat held paxvax all-cash
transact transact fund combin emerg
exist cash credit facil acquisit add two
market vaccin emerg portfolio vivotif oral live typhoid vaccin
vaxchora oral live vaccin cholera product market intern
travel whose destin includ high-risk area compani also gain access
paxvax cgmp product facil us switzerland file paxvax
financi follow acquisit report net product revenu
emerg also acquir adapt pharma privat up-front payment
sales-bas mileston up-front payment includ
cash stock adapt pharma lead product narcan intranas
formul naloxon drug treat opioid overdos anthrax franchis
anticip narcan becom second import driver top line
manag guid revenu deal narcan price
carton qualifi group buyer emerg
servic personnel take mid-point price manag guidanc impli
annual demand narcan dose carton bottom rang
manag comment mix narcan sale split retail
public interest market impli weight averag sell price close
recent joint aadpac/dsarm adcom discuss naloxon co-prescrib opioid
eventu vote narrowli favor co-prescrib
consensu whether naloxon co-prescrib opioid medic best path
forward due project cost program potenti altern
strategi speaker highlight potenti demand naloxon certain
scenario fda present highlight mandatori co-prescrib naloxon
would requir dose annual manag present data state
current co-prescrib requir va vt az ri fl wa ca initi
present note patient mme
well short fda long-run estim panelist fda present note
discrep continu agenc would need take step increas
adopt narcan account naloxon prescript fill base
data present compani believ product capac
carton dose per year expect increas carton
dose would evalu ad addit capac respons increas
summar iqvia data narcan well evzio naloxon autoinjector
gener formul manag comment iqvia captur major
retail market monthli prescrib increas significantli begin
part due co-prescrib ca may moder time experi
state steady-st level scrip remain significantli pre-
iqvia cowen compani
iqvia cowen compani
busi ebss fill/finish busi produc revenu
ramp manag indic expect continu
expand capac busi beyond receiv ciadm
design allow surg capac manufactur product emerg
medic need barda send compani need contract manufactur
aid emerg believ collabor provid busi
develop lead june announc expans camden
fill/finish facil locat baltimor md expect complet
acquisit paxvax includ manufactur facil near bern switzerland
manag believ allow compani better attract european client
make progress toward long-term goal emerg financi goal call
total revenu revenu outsid us net expens
net revenu sg expens total revenu addit
compani increas target non-gaap net incom revenu result
favor tax rate chang manag look attain goal
increas product sale grant contract revenu busi
revenu emerg expand intern sale forc increas
sg work includ product advanc develop increas
expenditur develop pipelin product outsid contract-driven work
revenu guidanc meet first financi goal year earlier
origin project
invest thesi view lead biodefens contractor
grow non-biodefens portfolio fda approv build late increas
biothrax product capac howev follow-on govern contract
smaller anticip place biothrax growth prospect risk
manag emphas intent grow revenu earn organ
well acquisit
look clariti nuthrax develop manufactur valid
phase studi initi updat short long-term prospect narcan
biothrax raxibacumab vaxchora vivotif well busi
cowen compani
datestagemilestonebiothrax deliveri updatesnuthrax deliveri post-eua iiicomplet follow-on contract us govflu-igiv iistudi completionzika-ig zika therapeut itrial zika iful phase data cowen
expect cabometyx sale line consensu estim
despit strong competit rcc
cometriq face strong competit
expect total revenu potenti consensu line
cowen compani street consensu bloomberg
model updat lower total revenu estim
rais estim rais cabo sale
due strong rx growth new ep estim
earn summari report light revenu q/q
due time mileston revenu partner expect cabometyx sale
continu stabil pressur come competit merck
keytruda pfizer inlyta rcc larg off-set cabo growth rcc
scrip q/q januari receiv approv
fda cabometyx despit competit headwind see sale
grow y/i driven gain rcc cabometyx hold market
share rcc tki q/q grow segment believ cabometyx
achiev peak global rcc sale support stock valu
confer call topic topic discuss compani call like
includ cabometyx launch competit landscap rcc updat
clinic progress cabo combin across multipl tumor type includ nsclc
prostat cancer stem recent expans studi tnbc
endometri cancer endocrin tumor differenti thyroid cancer
discuss on-going cotel combin trial braf-mut melanoma
partner roch potenti impact failur braf-
wild type collabor roche/genentech melanoma updat
cabometyx sale commerci two formul cabozantinib tablet
formul brand cabometyx treatment advanc rcc
capsul formul brand cometriq approv medullari thyroid cancer mtc
physician recept toward cabometyx strong consult increasingli
view cabometyx best overal profil tki rcc
cabometyx sale slightli consensu due
slight inventori destock higher gross/net discount destock might revers
discount remain rang year
cabometyx estim q/q y/i slightli consensu
q/q y/i price cabometyx increas
prescript trend q/q suggest
cabometyx sale would track slightli
cowen compani iqvia
sale grown driven uptak
set stabl share tki
compar see strong uptak inlyta q/q growth
lenvima q/q growth increas competit pressur
inflect cabometyx demand appear driven decemb label
expans treatment patient first-lin advanc rcc believ cabo
potenti rcc market market dynam
competit bristol myer opdivo yervoy io io combin therapi expect
captur major first-lin share short term consult envis cabometyx
use patient dont toler io therapi also expect cabometyx
benefit opdivo exit second-lin market provid cabometyx room
move
expect io tki regimen competit first-lin set
shown dual os/pf benefit keytruda inlyta april fda approv
keytruda/inlyta rcc month ahead pdufa kol think
keytruda/inlyta domin caveat therapi long-term
surviv benefit toler
anticip data cabometyx opdivo cosmic-
cabometyx tecentriq strong bar high key question
whether demonstr clinic meaning
differenti term efficaci safeti sinc cabometyx combin
therapi behind develop
april bmy/exel announc checkmat complet enrol minor
increas sampl size data expect earli vs
previous slight push-out due shorter patient random studi
anticip studi abl show benefit first look
remain seen whether achiev os first look
continu develop cabometyx addit oncolog indic effort
broaden drug franchis clinicaltri gov indic
cabozantinib clinic trial on-going sponsor outsid rcc mtc
sever trial studi cabometyx combin io agent
bmi opdivo roch tecentriq decemb announc initi
phase pivot trial cabometyx combin tecentriq versu
sorafenib previous untreat advanc hepatocellular carcinoma co-
primari endpoint trial progression-fre surviv overal surviv
exploratori arm also evalu cabometyx monotherapi first-lin set
partner ipsen takeda ex-u metyx approv rcc
europ septemb februari struck deal ipsen
cabo ex-u /ex-japan right ipsen launch cabometyx eu well
nordic countri austria netherland addit reimburs
discuss progress march chmp grant partner ipsen
applic cabometyx first-lin advanc rcc posit opinion
record mileston revenu cash receiv
ipsen approv cabometyx eu rcc canada
earli partner cabometyx takeda japan receiv
up-front payment elig potenti develop
regulatori first-sal mileston well tier royalti first
cabometyx sale follow royalti takeda begun
phase ii bridg studi cabo support regulatori file japan
minnebro partner daiichi japan januari announc
partner daiichi sankyo receiv approv japanes ministri
labor welfar mhlw esaxerenon minnebro treatment patient
hypertens expect receiv mileston payment
upon first commerci sale minnebro japan mileston
payment trigger daiichi regulatori file record
cometriq sale mtc repres small opportun cometriq given estim
patient affect off-label use rcc cometriq
declin demand revert level consist nearli fulli
penetr mtc market drug also studi singl agent
radioiodine-refractori dtc market present market opportun
phase studi initi octob top-lin data
expect
cometriq sale q/q believ drug
remain low interest investor
digit ex-u royalti cotel roch mek inhibitor approv combin
zelboraf braf mutant-posit unresect metastat melanoma given profit
share natur collabor modest opportun melanoma
dont expect meaning revenu near term cotel sale
multipl cotel combin therapi develop roch put much focu
develop cotel combin agent includ inhibitor
tecentriq avastin roche/abbvi venclexta clinicaltri gov list
on-going studi variou cotel combin studi solid liquid tumor
phase ii neo-vc studi evalu neoadjuv treatment cotel zelboraf
braf mutant-posit melanoma way june roche/exelixi
announc phase trial evalu cotel tecentriq wild type
braf metastat melanoma fail meet primari endpoint phase trilog trial
cotel tecentriq zelboraf combin treatment-nav
mutation-posit patient advanc melanoma still way trilog
initi base posit phase data orr includ cr rate
cabometyx launch updat eu potenti data phase ii neo-vc
braf mutant-posit melanoma
invest thesi integr compani two market drug
cabometyx cotel lucr oncolog market drug oral tki
strong data global partnership lead product cabometyx key driver
valuat prospect drug seen robust uptak sinc approv
rcc cabometyx sale driven strong growth end user demand
believ cabometyx potenti rcc/hcc januari drug
receiv approv import smaller market opportun expect
cabometyx remain reliabl growth driver compani top-lin growth
due on-going share gain across rcc new io/tki combo
pfizer inlyta recent approv base robust result rcc cabometyx
like come pressur segment regimen approv
earli henc key sustain growth rcc
think estim consensu appear achiev given
inventori follow drawdown could drive upsid
estim consensu biktarvi launch well
 q/q
analysi suggest estim street consensu may
low given rapid growth epclusa prescript
consensu assum patient treat equat
per certifi center consist treatment rate
appear reason
upsid hiv hcv franchis could yield total revenu
estim
street consensu hiv/hbv sale hcv sale yescarta revenu total revenu pro forma ep ep bloomberg
cowen compani
report date tuesday juli gilead host confer call et
code
earn comment overal expect solid quarter gilead potenti upsid
hiv hcv franchis could yield total revenu non-gaap ep
estim consensu biktarvi fifth full quarter sale provid
boost hiv franchis continu off-set declin prescript gilead
hiv regimen gilead hcv franchis experienc robust growth scrip
q/q driven uptick prescript epclusa q/q
epclusa growth partli driven on-going launch author
gener gilead subsidiari believ gilead stock continu
under-valued project cash flow dcf-base price target remain
nonetheless hiv franchis face patent expiri next sever
year gilead prospect long-term top-lin growth appear middl fact
project product sale compound-annual-growth-rate gilead recent expans glpg
collabor add new candid larg market pipelin step
right direct though risk candid remain none yet proven
like blockbust suspect major rerat share requir
better visibl pipelin candid capabl drive meaning reacceler
biktarvi world-wide hiv/hbv estim q/q y/i
consensu approxim q/q y/i estim includ
 sale q/q y/i ex-u sale q/q
y/i analysi suggest world-wide hiv revenu estim reason
 hiv/hbv franchis sale estim includ project viread vemlidi
odefsey tybost symtuza vitekta gilead indic
 hiv franchis sale flow privat pay channel track iqvia
sale reimburs public payor includ state adap
program veteran administr public health system therefor
one must care predict quarterli result much certainti
iqvia prescript data sale government-reimburs channel
track iqvia nonetheless iqvia data best sourc inform
access therefor acknowledg caveat
inform compar current scrip trend estim
 number incorpor viread/vemlidi sale estim
q/q viread trx q/q combin viread/vemlidi
prescript q/q sale benefit price increas
viread vemlidi institut march take scrip trend price increas
account assum gilead captur wac price increas viread/
vemlidi appear track toward revenu q/q
 truvada/descovi estim q/q truvada/
descovi scrip q/q march price truvada
descovi increas consid prescript trend price
increas combin truvada/descovi sale appear track toward
q/q atripla estim q/q
atripla scrip q/q partial offset impact atripla
prescript trend price increas institut march togeth
prescript trend price increas impli atripla revenu track toward
q/q complera/odefsey estim
q/q iqvia-report complera/odefsey prescript q/q
march price complera odefsey increas
togeth prescript trend price increas impli combin revenu track
toward q/q stribild/genvoya/biktarvi estim
q/q moreov march price stribild genvoya biktarvi
increas combin growth prescript late price increas
impli combin revenu track toward q/q
emtriva/vitekta/tybost/symtuza estim q/q scrip modest
four think estim reason
iqvia cowen compani
altogeth iqvia prescript trend suggest hiv franchis sale
approxim q/q estim q/q
q/q y/i vs demand trend busi
remain strong prescript y/i howev gilead note
report revenu advers impact inventori drawdown season
shift payor mix toward public payor gilead estim combin factor
result approxim headwind simpli assum meaning chang
inventori level q/q would impli hiv revenu would approxim
q/q estim q/q meaning re-
stock inventori level channel would contribut addit upsid
total hiv franchis growth rapid growth biktarvi prescript
q/q off-set declin prescript gilead hiv regimen
total iqvia-report prescript gilead hiv franchis grew q/q
iqvia cowen compani
ex-u hiv franchis ex-u hiv franchis estim q/q
y/i vs dhring notabl first gener viread truvada
atripla enter eu market juli rather steep revenu declin start
anticip launch biktarvi addit european countri
launch itali expect mid-year help off-set impact
gener without scrip data visibl ex-u sale low nonetheless
think estim appear reason
take account prescript trend ex-u sale think
world-wide hiv estim q/q y/i consensu
q/q y/i achiev restock wholesal
world-wide hcv franchis revenu estim q/q
y/i street consensu q/q y/i estim
includ sale q/q y/i eu sale q/q
y/i intern sale q/q y/i overal
estim street consensu appear conserv given rapid growth epclusa
prescript q/q
unit state iqvia record harvoni trx q/q
nrx q/q iqvia record epclusa trx q/q nrx
q/q iqvia record vosevi scrip q/q nrx
q/q iqvia-record sovaldi prescript nrx rapid growth
epclusa prescript off-set declin prescript gilead hcv
regimen altogeth iqvia record gilead hcv franchis q/q
nrx q/q
robust growth gilead hcv franchis q/q driven
uptick prescript epclusa q/q epclusa growth boost
on-going launch author gener epclusa launch gilead subsidiari
asegua prescript ag nearli tripl made
total epclusa scrip end quarter
iqvia health cowen compani
 hcv market q/q growth driven
expans prescript epclusa quarter prescript gilead
primari competitor hcv abbvi mavyret actual declin quarter
q/q allow gilead take back share gilead trx
share last week last week last
week last week last week
last week last week share chang
period base
commentari therapeut confer last octob expert expect
littl chang patient volum compar anticip volum
continu declin thereaft physician report reimburs longer
obstacl treatment regimen chosen base insur coverag given
similar efficaci conveni price physician anticip gilead
abbvi regimen captur approxim equal share hcv market given
commentari hope histor declin gilead franchis
continu moder next quarter
gilead report harvoni revenu epclusa revenu
 vosevi revenu therefor iqvia prescript trend
would impli harvoni sale q/q epclusa sale
q/q vosevi sale q/q
togeth figur suggest total hcv franchis revenu
q/q y/i would well q/q y/i
iqvia health cowen compani
gilead previous suggest price per patient genotyp
converg price week genotyp patient due competit
mavyret mavyret price monthli wac would impli
averag net price per patient gilead report treat
patient total hcv revenu impli averag net
price per patient impli price discount
wac cours mavyret gilead suggest averag net price
larg stabil gilead newli launch subsidiari
begun offer author gener epclusa harvoni gilead expect
gener reduc patient cost expand access begin grow market
share medicaid market gilead indic list price
author gener gener epclusa gener
harvoni compar net price brand version
given increas sale volum wholesal would need keep inventori
channel assum maintain two week inventori would
approxim inventori channel end would
need inventori end suggest increas
channel inventori could also increas report revenu approxim
overal analysi suggest hcv revenu q/q y/i
well estim q/q y/i
outsid harvoni record ex-u sale q/q
y/i epclusa ex-u sale q/q y/i vosevi ex-
 revenu q/q y/i total ex-u hcv sale
q/q y/i gilead note number new patient start
intern market unchang
total ex-u hcv estim q/q y/i
without prescript data limit visibl eu trend y/i declin
project reflect continu declin patient volum earli launch
bolu continu subsid well impact abbvi mavyret think
assumpt reason though way verifi
overal analysi impli world-wide hcv franchis revenu estim
q/q y/i street consensu q/q y/i
may underestim report revenu nonetheless find difficult
much convict report given lack visibl trend
 price ex-u util
yescarta project yescarta revenu q/q consensu
q/q consensu suggest yescarta account
gilead revenu perform meaning impact gilead
 nonetheless gilead pay acquir kite yescarta
perform like outsiz impact sentiment toward gilead stock
gilead disclos earn call treatment center certifi
prescrib yescarta eu new center continu
author gilead indic focu shift increas patient flow
gilead anticip adopt gradual improv center gain experi
yescarta approv eu august gilead continu add certifi
site europ obtain reimburs germani franc
anticip european approv yescarta gilead previous leas manufactur
facil netherland come on-lin full year revenu
yescarta gilead previous guid increment
impli nearli doubl revenu compar q/q
growth launch continu ramp yescarta expand european
yescarta list price per patient consensu estim would suggest
patient treat yescarta estim would impli
consensu estim would translat patient treat per certifi
center across eu site report revenu suggest
approxim patient per center estim consensu
consist pace would appear reason though visibl low
geograph distribut product sale gilead product sale
 europ intern
oper expens total oper expens estim q/q
y/i project non-gaap gross margin estim non-gaap
expens revenu q/q y/i project non-gaap sg
revenu q/q y/i
tax rate model assum tax rate gilead guidanc
non-gaap effect tax rate
ep non- ep estim q/q y/i estim
q/q y/i bloomberg consensu call non-gaap ep
q/q y/i ep q/q y/i
thesi investor wait gilead revenu stabil three
year declin gilead guidanc impli product sale growth
suggest overal gilead busi final plateau expect gilead
hcv busi continu contract becom rel minor part gilead
top line launch taf regimen gilead hiv
franchis continu bright spot anticip y/i growth
appear capabl compens hcv trend well loss exclus
letairi ranexa though hiv competit increas gilead leadership posit
seem safe next sever year therefor day precipit declin
gilead revenu appear past believ gilead stock continu
under-valued project cash flow dcf-base price target
gilead hiv franchis also face patent expiri next
sever year gilead prospect long-term top-lin growth appear middl fact
project product sale compound-annual-growth-rate suspect major re-rat
like requir visibl pipelin candid capabl drive meaning
reacceler revenu
look initi phase ii studi ulcer
coliti initi phase studi selonsertib diabet kidney diseas complet
enrol phase ii remdesivir ebola survivor complet enrol
pivot phase ii adult complet phase studi
vesatolimod hiv cure data phase ib studi capsid
inhibitor data phase ii studi nrti data phase ii gs-
cutan lupu erythematosu data phase ii sjogren
syndrom data pivot phase ii mcl file ema
approv filgotinib rheumatoid arthriti
cowen compani consensu thomson reuter
thesi glycomimet leverag deep scientif expertis
discov develop commerci novel medicin diseas
phase trial vaso-occlus crisi voc sickl cell diseas scd
data expect analysi scd voc repres larg unmet medic
need rivipansel potenti peak market opportun uproleselan
e-selectin antagonist gener promis phase data
aml patient show chemo potenti meaning improv respons rate
standard care phase r/r aml trial on-going data expect
drug also current two phase studi newli diagnos aml patient
believ uproleselan could becom key adjunct therapi multipl blood cancer
model potenti peak sale aml alon pipelin asset
inhibitor e-selectin current phase preclin data suggest gmi-
enhanc abil chemotherapi target improv surviv high-
risk form mutat aml
rivipansel pan-selectin antagonist partner test phase
pivot trial voc crisi scd data expect releas like
selectin mechan valid previou preclin clinic dataset
deliv clinic outcom includ strong result novarti p-selectin
antagonist crizanlizumab believ rivipansel pan-selectin activ
like translat higher benefit one show crizanlizumab inde
previou phase rivipansel voc data demonstr strong proof concept
includ dramat reduct opioid use well time discharg readi
primari endpoint phase time resolut crisi power
increas phase studi see good probabl drug hit
primari endpoint also view decreas use opioid like key
secondari endpoint given current polit environ around opioid epidem
enrol studi recent complet delay time guidanc
top-lin data late believ data releas
like occur given timeli upcom data releas anticip
provid detail data preview clarifi expect
view scd voc repres larg unmet medic need voc-rel
hospit per year us estim rivipansel potenti peak
market opportun per agreement entitl remain mileston
next potenti payment trigger upon potenti nda
file accept subsequ first commerci sale us
also elig receiv tier royalti low singl digit low teen ww net sale
base report patient trend think like epidiolex
beat estim consensu
focu investor
focu investor
cowen compani consensu epidiolex sale gw pharma consensu sativex ep bloomberg
earn comment launch epidiolex earli quarter investor focu
squar perform prospect continu growth base
physician check well recent prescript trend think epidiolex like
beat estim consensu
call discuss topic expect gw confer call focu updat
metric epidiolex launch includ patient trend dose discontinu
epidiolex long-term growth potenti european market potenti epidyolex
like epidiolex estim q/q consensu
first full quarter marketgw report net sale
well ahead consensu compani call
manag provid metric suggest epidiolex promis trajectori
long-term growth end march patient receiv dispens
medic prescrib new patient enrol form
physician gener dispens prescript novemb
decemb payor coverag also encourag commerci live
peopl coverag determin cover either prior
author prior author label addit manag medicaid
live coverag determin prior author prior
author label state fee servic medicaid live
prior author prior author label compani also
notic increas number adult patient initi treatmentat rate
gw manag provid epidiolex revenu guidanc sever
metric suggest epidiolex continu penetr market compani
earn call manag caution epidiolex revenu reflect bolu
due earli launch pent-up demand carri forward decemb earli
coverag determin patient earli access program open-
label extens trial transit commerci product howev manag also
note new patient start continu aprilthough somewhat slower
rate
gwph report q/q revenu estim
q/q consensu q/q assum epidiolex
penetr refractori epilepsi market includ approv use dravet
lennox-gastaut addit off-label prescrib broader epilepsi popul
increas approxim q/q point comparison epidiolex
penetr refractori epilepsi market increas almost rel
account fact includ two month revenu follow
epidiolex novemb launch thu estim consensu suggest continu
adopt though somewhat slower pace
base physician check iqvia scrip trend believ gw abl
gw manag state scrip number inaccur prescript
trend inform growth end-us demand epidiolex
exampl end march gw report patient receiv dispens
epidiolex iqvia report period launch march
therefor total number prescript iqvia under-report number
written nonetheless q/q growth epidiolex q/q
inform though perhap overst q/q growth revenu
scrip q/q prescript trend adequ reflect
growth end user demand assum stabl per patient averag price trend
would suggest revenu q/q growth prescript
overst revenu growth mean q/q growth epidiolex
sale track toward instead revenu would
either case prescript trend suggest like upsid estim consensu
cowen compani iqvia
physician check suggest rapid uptak epidiolex sinc launch
like continu panelist march confer
involv gw clinic program year time epidiolex
approv patient take epidiolex patient roll
onto commerci drug initi addit patient onto commerci
drug sinc approv though sever patient offici diagnos lg
dravet note major patient form epilepsi
panelist expect epidiolex wide use among patient dravet epidiolex
first fda-approv drug treatment dravet diacomit stiripentol
also approv dravet europ yet avail note
strong interest patient commun epidiolex expect mani dravet
patient least tri also optimist widespread use
wider popul patient refractori epilepsi think open
payor determin extent off-label uptak thu far happi
interact payor abl obtain reimburs patient
offici diagnosi lg dravet
plural respond march pre-confer survey expect
first full year market epidiolex captur patient label
indic lg dravet unsurprisingli specialist somewhat temper
expect penetr broader mostli off-label pediatr adult
refractori epilepsi popul respond predict
penetr nonetheless would still repres rapid uptak divers
cowen compani confer
cowen compani confer
physician check impli continu rapid growth epidiolex util
think help corrobor iqvia prescript trend
similarli impli epidiolex sale estim consensu assum
meaning deceler epidiolex launch like conserv
epilepsi ask predict uptak epidiolex three year among patient
lg dravet survey physician predict penetr
substanti broader popul refractori epilepsi patient plural
physician expect penetr three year panelist
health confer march believ given wide interest awar
epidiolex among patient mani tri epidiolex initi number remain
therapi howev difficult predict mani insur requir yearli re-
assess anti-epilept drug ensur continu provid benefit
panelist think least one-third patient refractori epilepsi take
epidiolex three year due larg pool patient fail
altern option
specialist anticip wide adopt dravet lg
cowen compani confer
cowen compani confer
chmp opinion epidiolex expect immin epidiolex file
ema gw optimist posit chmp decis prepar
commerci launch major european market underway manag
guid well prepar term manufactur capac meet anticip
demand europ gw plan launch epidiolex initi
addit european countri
invest thesi gw epilepsi program major driver valu stock
recent approv epidiolex oral liquid formul highli purifi extract
cbd demonstr compel efficaci multipl intract form epilepsi
dravet lg follow reschedul end septemb epidiolex
launch novemb believ epidiolex broadli use
across refractori epilepsi on- off-label support global sale
think gw stock under-valued potenti epidiolex dcf-base price
target
look chmp opinion epidiolex dravet lg possibl
launch epidyolex european brand name select european territori franc
germani itali spain uk
aloxi gener arbitrag start anticip
continu
sept
focu investor
cowen compani consensu thomson reuter
earn summari revenu estim includ sustol
cinvanti line consensu sustol
cinvanti compani issu cinv revenu guidanc
view appropri conserv light extend aloxi gener
arbitrag potenti emend iv gener arbitrag late cinv
franchis beat guidanc ep major focu investor
although estim slightli consensu heron end
cash/equival short-term invest believ
compani suffici capit reach key mileston includ
resubmiss regulatori action
cinv franchis pois growth august fda approv sustol first
extended-releas receptor antagonist prevent acut delay
nausea vomit associ moder emetogen chemotherapi
anthracyclin cyclophosphamid combin chemotherapi regimen ac-
base regimen specif sustol brand inject class obtain
indic delay ac-bas regimen one commonli
competitor eisai aloxi lack label delay hec aloxi previou
market leader gener sale last year gener
annual demand estim unit importantli teva announc launch
gener version aloxi march sever formul
launch well result monthli aloxi sale record iqvia come
gener erod franchis despit trend asp gener fallen
slowli expect sustol face discount longer origin
anticip januari heron present inform indic asp
administr aloxi palonosetron fell
heron present data june indic declin gener asp
acceler compani previous project asp drop
actual asp compani project asp fall versu
previous asp palonostreon drop slowli compar
observ zofran/ondansetron gener arbitrag result gener
manufactur becom disciplin price believ dynam leav
sustol posit prefer drug out-pati set medicar part-b
reimburs mechan heron took price increas sustol june
wac per pre-filled syring aloxi wac drop per
vial result gener pressur
short term continu anticip weak sustol due
increas discount compet aloxi gener physician abl use
gener aloxi receiv reimburs histor brand aloxi price
model y/i decreas sustol sale due extend arbitrag
anticip growth pressur aloxi gener pass also
believ even add asp reduc incent doc use
sustol remain due step taken heron differenti drug heron
collect addit data order demonstr sustol benefit aloxi
background antagonist dexamethason common triplet combo
patient receiv sustol requir hydrat versu aloxi final sustol
receiv perman j-code januari streamlin
iqvia cowen compani
drive cinv franchis heron launch cinvanti januari
wac juli cinvanti heron formul
aprepit antagonist lack surfact polysorb
formul associ fewer teae compar current market
leader emend iv addit compani present data indic iv
push cinvanti similar safeti profil compar standard
infus includ label
iqvia cowen compani
cinvanti complementari product sustol target major pathway
underli cinv two drug frequent administ patient
highli concentr natur prescrib practic also assist market
cinvanti januari compani note signific underutil
antagonist hec patient heron previous report approxim
patient hec regiment receiv therapi despit nccn guidelin
recommend use patient regimen receiv
suggest even larger market opportun hrtx cinv franchis suggest
current market leader aloxi emend iv februari cinvanti
receiv label expans administr via iv push includ
emend label heron report intern data indic cinvanti captur
market share clinic hospit despit enter
market larg establish franchis cinvanti uniqu j-code januari
heron also report data indic cinvanti take market share
expand market antagonist
heron announc fda issu complet respons letter follow
review nda compani fixed-dos formul bupivacain
meloxicam request addit non-clin inform
commun agenc indic new trial re-analysi clinic data
requir letter appear last-minut surpris review
process manag state issu includ inform request
review process compani plan prepar background document
request type meet fda soon possibl discuss path
resolv issu identifi observ follow inspect
lifecor chaksa mn facil one heron supplier least one reason
issu highlight fda appear fall two broad categori drug
qualiti control procedur record keep overal believ manufactur
issu solvabl continu believ best-in-class profil
launch anticip resubmiss allow new pdufa
maintain track breakthrough therapi design cash
perspect compani well capit requir financ htx-
expect investor primarili focus heron pain franchis
drug candid heron phase pain drug combin
bupivacain meloxicam biochronom delay releas formul phase
studi post-op pain report posit top-lin data march
studi show provid superior pain control compar
gener bupivacain clear separ pain score hour
bunionectomi hour hernia repair addit significantli fewer patient
requir opioid rescu medic addit phase iib trial report posit data
june tka breast augment
opioid spare compar activ control arm benefici heron
collect opioid-spar data month follow-on studi combin
common over-the-counter analges dont anticip data adequ support
opioid spare claim sinc fda yet guid data requir
believ potenti mention data label still commerci
valuabl also expect compani would make data avail physician
confer market materi
compani also initi studi enrol adult undergo open
inguin herniorrhaphi mesh june pilot cohort patient
treat over-the-counter analges acetaminophen ibuprofen goal
avoid opioid prescrib entir patient patient complet opioid-
free recoveri remain opioid pre-discharg patient
receiv discharg opioid prescript pill versu typic
prescript patient actual took opioid post-discharg
extrapol data inguin hernia heron believ protocol would result
fewer opioid pill consum fewer pill leftov
vulner divers program test nation
closest brand competitor pacira exparel current approv long-
act version bupivacain without meloxicam anti-inflammatori compon
believ investor look exparel sale
refer potenti howev view develop
program give import advantag exparel specif compar arm
gener bupivacain efficaci hour posit best-in-
heron also disclos second extend durat local anesthet current
preclin develop pig post-operative pain model demonstr pain control
day compar favor liposom bupivacain salin
pig model detail formul mechan action improv
disclos compani plan initi phase ii trial
cowen compani
invest thesi heron commerci biotechnolog compani
use proprietari biochronom polymer-bas drug deliveri platform improv
therapeut profil inject pharmaceut control drug releas
extend durat action heron two approv drug chemotherapi
induc nausea vomit sustol cinvanti believ primari valu
pain drug complet multipl phase ii studi well pivot
phase trial consist show strong result believ
best-in-class opioid altern come ideal time medic
commun move away opioid post-surg pain manag
datestagemilestonesustol cinv commerci post-op approv cinvanti cinv lanch post-op iiiniti trial cowen
steadi growth demand improv net price drive in-lin
limit visibl modest upsid possibl
consensu easili achiev royalti stream expect
minim unless dvt/pe issu resolv
ep yet major focu investor
street consensu incyt
cowen compani
report date tuesday juli host confer call et
code jakavi partner novarti report juli
olumi partner lilli report juli
earn summari jakafi experienc solid growth myelofibrosi mf
polycythemia vera pv indic relief season impact donut hole
drive rebound jakafi net price meanwhil expect jakafi/jakavi
demand growth continu apac lead sale line expect incyt
call focu long-term growth prospect jakafi mf pv well
emerg pipelin opportun includ fgfr inhibit cholangio bladder
cancer gvhd topic jak inhibitor
jakafi solid trajectori inclus season donut hole-rel headwind
jakafi revenu q/q y/i manag report jakafi
inventori level enter exit normal level week therefor
inventori enter normal rang year-over-year growth primarili
driven growth patient volum myelofibrosi mf polycythemia
vera pv indic grew y/i respect incyt
earn slide indic mf pf patient jakafi
estim patient elig jakafi indic therefor
much room growth remain anticip volum growth continu along
long-term trajectori least q/q growth would impli
gross demand
gross-to-net adjust adjust higher normal
due donut hole liabil first quarter year contribut
increment adjust manag guid
adjust full year thu estim
adjust approxim would repres q/q net price increas
taken togeth growth prescript demand net price would suggest
report jakafi sale q/q y/i consist
consensu model
jakavi expand ex-u jakavi ex-u trade-nam partner novarti
outsid ema approv jakavi use pv march reimburs
secur canada franc germani japan spain territori
novarti report sale q/q follow q/q growth
prior quarter anticip jakavi maintain
long-term averag growth rate q/q base upon continu penetr
exist market well new launch
jakavi averag q/q growth perform individu quarter
fluctuat significantli somewhat weaker q/q perform project
see somewhat stronger averag q/q perform novartiss report
sale grow q/q report start new year incyt
tier royalti rate reset base upon histor royalti believ
entitl royalti sale royalti sale
royalti royalti
next tier reach therefor anticip receiv royalti
sale royalti remain sale would thu
book jakavi royalti somewhat consensu estim
file global approv inhibitor olumi baricitinib
treat ra earli consequ june fda approv baricitinib
dose due concern potenti associ
baricitinib dvt/te event potenti safeti risk reinforc februari
report post-market studi xeljanz anoth jak
inhibitor reveal risk blood clot believ baricitnib label
sever limit baricitinib commerci adopt dose
demonstr superior humira therefor gener conserv
rheumatologist ask take theoret safeti risk thrombosi littl
clinic benefit oral dose vs humira
olumi partnership entitl base tier royalti
base upon global olumi sale also elig pro-rat addit
royalti indic co-fund cost develop beyond proof-of-
concept phase ii earn call announc decis
discontinu co-fund lilli olumi develop program
previous opt on-going post-poc program olumi
current approv ra contribut fulli pivot develop
indic receiv royalti olumi sale
go forward base royalti expect trend olumi sale
continu ramp meanwhil supplement royalti like trend
expenditur dilut lilli continu effort olumi
anticip net effect royalti least
given earli stage launch concern toxic gener conserv
natur rheumatologist olumi expect produc modest sale lilli
report q/q global olumi sale q/q come
ex-u territori translat royalti pfizer
disclosur xeljanz blood clot risk februari trigger ema review led
